0001213900-20-037172.txt : 20201116 0001213900-20-037172.hdr.sgml : 20201116 20201116105347 ACCESSION NUMBER: 0001213900-20-037172 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201116 DATE AS OF CHANGE: 20201116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Heyu Biological Technology Corp CENTRAL INDEX KEY: 0001086303 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 870627910 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26731 FILM NUMBER: 201314521 BUSINESS ADDRESS: STREET 1: 4TH FLOOR, NO.10 BUILDING, XINGLIN BAY STREET 2: BUSINESS OPERATION CENTER JIMEI DISTRICT CITY: XIAMEN CITY, FUJIAN PROVINCE STATE: F4 ZIP: 361022 BUSINESS PHONE: 86 158 5924 0902 MAIL ADDRESS: STREET 1: 4TH FLOOR, NO.10 BUILDING, XINGLIN BAY STREET 2: BUSINESS OPERATION CENTER JIMEI DISTRICT CITY: XIAMEN CITY, FUJIAN PROVINCE STATE: F4 ZIP: 361022 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC WEBWORKS INC DATE OF NAME CHANGE: 19990715 10-Q 1 f10q0920_heyubiological.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission file number 000-26731

HEYU BIOLOGICAL TECHNOLOGY CORPORATION
(Exact name of registrant as specified in its charter)
Nevada		87-0627910
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Room 1901, Baotuo Building,

617 Sishui Street,

Huli District, Xiamen City,

Fujian Province, China

361009

(Address of principal executive offices)

(Zip Code)

(86) 158 5924 0902

(Telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		None		None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 1,032,466,000 shares of common stock as of November 13, 2020.

TABLE OF CONTENTS

Index to Form 10-Q

		Page
Part I

FINANCIAL INFORMATION

Item 1.	Financial Statements	1

	Condensed Consolidated Balance Sheets (Unaudited)	1

	Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)	2

	Condensed Consolidated Statement of Cash Flows (Unaudited)	3

	Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited)	4

	Notes to Condensed Consolidated Financial Statements (Unaudited)	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	18

Item 4.	Controls and Procedures	18

Part II

OTHER INFORMATION

Item 1.	Legal Proceedings	19

Item 1A.	Risk Factors	19

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19

Item 3.	Defaults Upon Senior Securities	19

Item 4.	Mine Safety Disclosures	19

Item 5.	Other Information	19

Item 6.	Exhibits	19

FORWARD LOOKING STATEMENTS

This quarterly report on Form 10-Q (“Report”), financial statements, and notes to financial statements contain forward-looking statements that discuss, among other things, future expectations and projections regarding future developments, operations, and financial conditions. Forward-looking statements may appear throughout this Report and other documents we file with the Securities and Exchange Commission (the “SEC”), including without limitation, the following section: Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Report.

Forward-looking statements generally can be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “will be,” “will continue,” “may,” “could,” “will likely result,” and similar expressions. These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause our actual results to differ materially from those reflected in the forward-looking statements. In addition, there is uncertainty about the spread of the Coronavirus Disease 2019 (“COVID-19”) and the impact it may have on the Company’s operations, the demand for the Company’s products or services, global supply chains, and economic activities in general. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Heyu Biological Technology Corporation

(Formerly known as Pacific Webworks, Inc.)

Consolidated Balance Sheets

(Unaudited)

	September 30,			December 31,
	2020			2019
ASSETS
Current Assets
Cash and cash equivalents	$	3,277		$	95,522
Accounts receivables		-			32,842
Other receivables, net		64,646			51,236
Prepaid expenses		27,427			-
Advances to suppliers		19,055			48,344
Inventory		481,438			421,533
Total current assets		595,843			649,477

Non-current Assets
Operating lease right-of-use asset		147,712			202,976
Total non-current assets		147,712			202,976

Total Assets	$	743,555		$	852,453

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts payable	$	17,152		$	80,700
Accrued expenses and other payable		236,599			30,674
Advances from customers		484,674			430,616
Income tax and other taxes payable		31			28
Operating lease liability - current portion		75,723			31,017
Related party payables		898,344			874,749
Total current liabilities		1,712,523			1,447,784

Noncurrent liabilities
Operating lease liability		74,655			172,610
Total noncurrent liabilities		74,655			172,610

Total Liabilities	$	1,787,178		$	1,620,394

Stockholders’ Deficit
Common stock ($0.001 par value, 2,000,000,000 shares authorized, 1,032,466,000 and 1,032,466,000 shares issued and outstanding respectively as of September 30, 2020 and December 31, 2019, respectively)		1,032,466			1,032,466
Additional paid-in capital		17,149,050			17,149,050
Accumulated other comprehensive income		(6,493	)		12,319
Accumulated deficit		(19,156,356	)		(18,909,705	)
Stockholders’ deficit - HYBT and Subsidiaries		(981,333	)		(715,870	)
Noncontrolling interests in subsidiaries		(62,290	)		(52,071	)
Total stockholders’ deficit		(1,043,623	)		(767,941	)

Total Liabilities and Stockholders’ Deficit	$	743,555		$	852,453

The accompanying notes are an integral part of these consolidated financial statements.

Heyu Biological Technology Corporation

(Formerly known as Pacific Webworks, Inc.)

Consolidated Statements of Operations and Comprehensive Income

(Unaudited)

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2020			2019			2020			2019

Revenue, net	$	16,600		$	7,387		$	52,383		$	49,930

Cost of Revenue	$	5,543		$	3,666		$	22,732		$	28,272

Gross Profit	$	11,057		$	3,721		$	29,651		$	21,658

Operating expenses
Selling expenses		301			5,992			6,527			1,385
Administrative expenses		88,037			202,505			280,134			209,702
Total operating expenses		88,338			208,497			286,661			211,087

Loss on operations		(77,281	)		(204,776	)		(257,010	)		(189,429	)

Other Expenses		(331	)		(370	)		(962	)		(1,337	)

Loss on operations before income taxes		(77,612	)		(205,146	)		(257,972	)		(190,766	)

Income tax expense		-			-			-			-

Net Loss	$	(77,612	)	$	(205,146	)	$	(257,972	)	$	(190,766	)
Loss attributable to noncontrolling interests		(2,407	)		(20,455	)		(11,321	)		(18,242	)
Net loss attributable to HYBT shareholders		(75,205	)		(184,691	)		(246,651	)		(172,524	)

Other Comprehensive (Loss) Income
Foreign currency translation adjustment		(24,912	)		12,506			(19,913	)		3,418
Total Comprehensive Loss	$	(100,117	)	$	(172,185	)	$	(266,564	)	$	(169,106	)
Total comprehensive (loss) income attributable to noncontrolling interests		2,339			(1,320	)		1,101			(226	)
Total comprehensive loss attributable to HYBT shareholders		(97,778	)		(173,505	)		(265,463	)		(169,332	)

Net loss per share - basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

Weighted average shares - basic and diluted		1,032,466,000			1,019,289,346			1,032,466,000			1,080,043,580

The accompanying notes are an integral part of these consolidated financial statements.

Heyu Biological Technology Corporation

(Formerly known as Pacific Webworks, Inc.)

Consolidated Statements of Cash Flows

(Unaudited)

	For the Nine Months Ended September 30,
	2020			2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$	(257,972	)		(395,913	)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in assets and liabilities
Accounts receivable		32,842			-
Other receivables		(13,410	)		(3,242	)
Prepaid expenses		(27,427	)
Advances to suppliers		29,289			(81,431	)
Inventory		(59,905	)		(311,134	)
Operating lease right-of-use asset		55,264			(209,587	)
Accounts payable and accrued liabilities		(63,548	)		95,090
Accrued expenses and other payable		205,925
Advances from customers		54,058			420,406
Income tax and other taxes payable		3			(1	)
Lease liability		(53,249	)		209,798
Net cash used from operating activities		(98,130	)		(276,014	)

CASH FLOWS FROM INVESTING ACTIVITIES		-			-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party lending		23,596			677,945
Net cash used in financing activities		23,596			677,945

Effect of exchange rate changes on cash		(17,711	)		12,832

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(92,245	)		414,763

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		95,522			37,555

CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	3,277		$	452,318

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest	$	-		$	-
Cash paid for income tax	$	-		$	-

The accompanying notes are an integral part of these condensed consolidated financial statements

Heyu Biological Technology Corporation

(Formerly known as Pacific Webworks, Inc.)

Condensed Consolidated Statements of Stockholders’ Deficit

(Unaudited)

	Heyu Biological Shareholders’ Equity
	Common Stock
	Number of shares			Par value			Shares to be cancelled			Additional Paid in Capital		Accumulated Other Comprehensive Income		Accumulated Deficit			Non - controlling Interest			Total

Balance at January 1, 2019		1,141,472,861			1,141,473			(109,007	)		17,149,050		2,567		(18,421,319	)		-			(237,236	)

Shares cancelled March 20, 2019		(109,006,861	)		(109,007	)		109,007			-		-		-			-			-
Foreign currency translation adjustment		-			-			-			-		14,378		-			(1,546	)		12,832
Loss for the period		-			-			-			-		-		(357,216	)		(38,697	)		(395,913	)

Balance at September 30, 2019		1,032,466,000		$	1,032,466		$	-		$	17,149,050	$	16,945	$	(18,778,535	)	$	(40,243	)	$	(620,317	)

	Common Stock								Accumulated
	Number of shares		Par value		Shares to be cancelled		Additional Paid in Capital		Other Comprehensive Income (Loss)			Accumulated Deficit			Non – controlling Interest			Total

Balance at January 1, 2020		1,032,466,000		1,032,466				17,149,050		12,319			(18,909,705	)		(52,071	)		(767,941	)

Foreign currency translation adjustment		-		-		-		-		(18,812	)		-			1,101			(17,711	)
Loss for the period		-		-		-		-		-			(246,651	)		(11,320	)		(257,971	)

Balance at September 30, 2020		1,032,466,000	$	1,032,466	$	-	$	17,149,050	$	(6,493	)	$	(19,156,356	)	$	(62,290	)	$	(1,043,623	)

The accompanying notes are an integral part of these consolidated financial statements.

Heyu Biological Technology Corporation

(Formerly known as Pacific Webworks, Inc.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

NOTE 1 – THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES

Heyu Biological Technology Corporation (the “Company”) was incorporated in the state of Nevada on May 18, 1987, as Asphalt Associates, Inc. and changed its name to Pacific WebWorks in January 1999. From 1999 to 2016 the Company engaged in the development and distribution of web tools software, electronic business storefront hosting, and Internet payment systems for individuals and small to mid-sized businesses. On February 23, 2016, the Company filed a voluntary petition for bankruptcy in the U.S. Bankruptcy Court for the District of Utah, and soon afterwards ceased its business activities. On August 19, 2016, the Company proposed a plan of liquidation and on November 28, 2016, the court entered an order confirming the plan of liquidation and establishing a liquidating trust. On December 28, 2016, all assets and liabilities of the Company were transferred to the liquidating trust.

On April 18, 2018, the Company entered into a share purchase agreement with Mr. Ban Siong Ang and Mr. Dan Masters (the “Share Purchase Agreement”), pursuant to which Mr. Ang acquired 1,021,051,700 shares, representing 98.91% of the issued and outstanding shares of common stock of the Company (“Common Stock”), from Mr. Masters for an aggregate purchase price of $335,000 (the “Share Purchase”). As a result of the Share Purchase, Dan Masters resigned from his positions as the President, Chief Executive Officer, Chief Financial Officer, Secretary and Chairman of the Board of the Company. Such resignations took place in connection with the closing of the Share Purchase and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Additionally, all debt due to Mr. Masters from the Company was cancelled as of the closing of the Share Purchase and recognized as contributed capital.

On April 18, 2018, to fill the vacancies created by Mr. Masters’ resignation, Ban Siong Ang and Hung Seng Tan were elected as the directors of the Company. Mr. Ang was appointed as President, Chief Executive Officer, and Chairman of the Board of the Company. Mr. Tan was appointed as the Executive Director of the Company. Ms. Wendy Li was appointed as the Chief Financial Officer of the Company.

On July 3, 2018, the Company changed its name to Heyu Biological Technology Corporation and applied for a new ticker symbol “HYBT”.

During 2018, the Company established the following subsidiaries: (1) HP Technology Limited, a British Virgin Islands business company incorporated on September 20, 2018, and (2) Heyu Healthcare Technology Limited, a Hong Kong company incorporated on March 29, 2018. On November 5, 2018, the Company acquired the following subsidiary: Jiashierle (Xiamen) Healthcare Technology Co., Ltd. (“JSEL”), a limited liability company incorporated under the laws of the People’s Republic of China (the “PRC”) on November 16, 2017.

On January 17, 2019, JSEL entered into a share transfer agreement (the “Share Transfer Agreement”) with Mr. Yu Xu (“Mr. Xu”), an individual with an address at No. 68 Chengde South Road, Qingpu District, Huaian City, Jiangsu Province, the PRC. Mr. Xu owned 90% of the equity interests of Shanghai Kangzi Medical Technology Co., Ltd., a limited liability company organized under the laws of the PRC (“Kangzi”). JSEL received 60% of the outstanding equity interest of Kangzi from Mr. Xu for the purpose of developing a joint venture in selling medical equipment. It was Mr. Xu and JSEL’s intention that JSEL would fund the operations of Kangzi in proportion to JSEL’s equity interest in Kangzi. At the time of the share transfer, Kangzi owned no assets and conducted no business operation.

Since the beginning of 2019, Mr. Xu has led the core research and development team of Kangzi to develop and manufacture a new medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the “Chamber”). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber. We believe that exposure to an appropriate amount of submillimeter waves would accelerate the generation of a large number of cosmic ray muons inside the human body and that such cosmic ray muons could further facilitate cold nuclear fusion, which could reverse the cancer by converting selenium into nickel inside cells.

Our team consists of researchers who have years of extensive experience in medicine and physics. The lead scientist of the team, Mr. Xu, had extensive professional experience in the aforementioned fields and has served as the deputy chief engineer of the New Energy Base of the National Defense-Science and Technology Commission in 1995, the chairman and chief scientist of Shanghai Guangzhui New Energy Technology Co., Ltd. from 2011 to 2019, and the director of Shanghai Hengbian New Energy Research Institute from 2003 to 2008. In 2012, Mr. Xu received the “Harmony-Person of the Year in China” award at the “2011 Harmony China Annual Summit” in Beijing. He was recognized as “Leaping China: One of the Most Influential People of the Year in 2011” by China International Economic and Technical Cooperation Promotion Association, China Elite Culture Promotion Association, and China Outstanding Chinese Merchants Association. Mr. Xu also received the “2013 China Economic Outstanding Contribution Award” from the Organizing Committee of Boau Forum on Asian SME Development.

Pursuant to the terms of the share transfer agreement entered into by JSEL and Kangzi on January 17, 2019, JSEL has the right to monitor and manage all aspects of operation of Kangzi, including its research and development activities relating to the Chamber. As the development of the Chamber enters its final stage, JSEL started accepting pre-orders for the Chamber in September 2019.

The outbreak of the novel coronavirus, commonly referred to as “COVID-19”, first found in mainland China, then in Asia and eventually throughout the world, has significantly affected business and manufacturing activities within China, including travel restrictions, widespread mandatory quarantines, and suspension of business activities within China. These measures have caused substantial disruptions to our business operations. We suspended our business operation in early February 2020 due to government mandates. We partially recovered our business operation on February 17, 2020, and on March 1, 2020, most of our staff members returned to the office and we fully resumed our business operations on the same day. Accordingly, our business, results of operations and financial condition were adversely affected. As of the date of this Report, Chinese industries have gradually resumed businesses as government officials started to ease the restrictive measures since April 2020. However, as most of our top management team is an overseas team, due to the international travel ban, we still operate under remote-working conditions, so the business of the Company is still recovering. Our management believes that our revenues will gradually improve as the epidemic and the travel ban are lifted.

On March 17, 2020, we entered into a business service cooperation agreement with Xiamen Qingda Intelligent Technology Co., Ltd., a wholly-owned subsidiary of Cross-strait Tsinghua Research Institute, pursuant to which we agreed to jointly improve the plant based disinfectant spray for treating skin infections and disinfecting wounds. The term of such agreement is three years, and can be renewed upon mutual agreement of both parties. The original plant based disinfectant spray was developed and owned by the Company, while the improved product shall be owned by both the Company and the Cross-strait Tsinghua Research Institute. The Cross-strait Tsinghua Research Institute will receive 2% of gross proceeds from the sales of such improved product. By September 30, 2020, we have had generated revenues of approximately $21,796 through sales of the improved product.

Basis of Presentation

The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation.

The condensed consolidated financial statements of the Company as of and for the three and nine months ended September 30, 2020 and 2019 are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) that have been made are necessary to fairly present the financial position of the Company As of September 30, 2020, the results of its operations for the three and nine months ended September 30, 2020 and 2019, and its cash flows for the nine months ended September 30, 2020 and 2019. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The balance sheet as of December 31, 2019 has been derived from the Company’s audited financial statements included in the Form 10-K for the year ended December 31, 2019.

The statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the financial statements and other information included in the Company’s Annual Report on Form 10-K as filed with the SEC for the fiscal year ended December 31, 2019.

As of September 30, 2020, the details of the consolidating subsidiaries are as follows:

Name of Company	Jurisdiction of Formation	Attributable equity interest %
HP Technology Limited	British Virgin Islands		100	%

Heyu Healthcare Technology Limited	Hong Kong		100	%

JSEL	PRC		100	%

Kangzi	PRC		60	%

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however, actual results could differ from these estimates. Significant estimates include the allowance for doubtful accounts, impairment assessments of goodwill, valuation of deferred tax assets, rebilling collections and certain accrued liabilities such as contingent liabilities. As of September 30, 2020, the Company considered the economic implications of the COVID-19 pandemic on its significant judgments and estimates. Given the impact and other unforeseen effects on the global economy from the COVID-19 pandemic, these estimates required increased judgment, and actual results could differ from these estimates.

Cash Equivalents

The Company considers all highly liquid debt instruments purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying unaudited condensed consolidated balance sheets for cash and cash equivalents approximate their fair value. All of the Company’s cash that is held in bank accounts in the PRC and Hong Kong is not protected by Federal Deposit Insurance Corporation (“FDIC”) insurance or any other similar insurance in the PRC, or Hong Kong.

Accounts receivable and allowance for doubtful accounts

Accounts receivable are stated at the historical carrying amount net of allowance for doubtful accounts. The Company maintains an allowance for doubtful accounts which reflects its best estimate of amounts that potentially will not be collected. The Company determines the allowance for doubtful accounts taking into consideration various factors, including but not limited to historical collection experience and credit-worthiness of the debtors, as well as the age of the individual receivables balance. Additionally, the Company makes specific bad debt provisions based on any specific knowledge the Company has acquired that might indicate that an account is uncollectible. The facts and circumstances of each account may require the Company to use substantial judgment in assessing its collectability.

Inventories

Inventories consist of finished goods, work in process, and raw materials. Inventories are stated at the lower of cost or market value. The Company applies the weighted average cost method to its inventory.

Leases

The Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which supersedes the lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements.

Operating leases are included in operating lease right-of-use (“ROU”) assets and short-term and long-term lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our consolidated balance sheets.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, we use the industry incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Adoption of the standard resulted in the initial recognition of $215,298 of ROU assets and $215,298 of lease liabilities on our consolidated balance sheet related to office space lease commitment on September 1, 2019.

ASU 2016-02 requires that public companies use a secured incremental browning rate for the present value of lease payments when the rate implicit in the contract is not readily determinable. We determine a secured rate on a quarterly basis and update the weighted average discount rate accordingly. Lease terms and discount rate follow.

	September 1, 2019
Weighted Average Remaining Lease Term(Year)		3
Weighted Average Discount Rate		4.75	%

The approximate future minimum lease payments under operating leases as:

	Operating Leases
Fiscal 2020		20,661
Fiscal 2021		83,533
Fiscal 2022		56,873
Total Lease payments		161,067
Less Imputed interest		10,689
Present value of lease liabilities	$	150,378

Foreign Currency

For fiscal year 2020, the Company’s principal country of operations is the PRC. The accompanying consolidated financial statements are presented in US$. The functional currency of the Company is US$, and the functional currency of the Company’s subsidiaries is RMB. The consolidated financial statements are translated into US$ from RMB at year-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transactions occurred. The resulting translation adjustments are recorded as a component of shareholders’ equity included in other comprehensive income. Gains and losses from foreign currency transactions are included in profit or loss. There were no gains and losses from foreign currency transactions during the quarters ended September 30, 2020 and 2019.

	As of
	September 30, 2020		December 31, 2019
RMB: US$ exchange rate		6.8013		6.9668


	Nine months ended September 30,
	2020		2019
RMB: US$ exchange rate		6.9941		6.8618

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.

General and administrative costs

General and administrative expenses include personnel expenses for executive, finance, and internal support personnel. In addition, general and administrative expenses include fees for bad debt costs, professional legal and accounting services, insurance, office space, banking and merchant fees, and other overhead-related costs.

Income Taxes

The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes. Income taxes are provided on an asset and liability approach for financial accounting and reporting of income taxes. Any tax paid by subsidiaries during the year is recorded. Current tax is based on the profit or loss from ordinary activities adjusted for items that are non-assessable or disallowable for income tax purpose and is calculated using tax rates that have been enacted or substantively enacted at the balance sheet date. ASC Topic 740 also requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carry-forwards. ASC Topic 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets, including those related to the U.S. net operating loss carry-forwards, are dependent upon future earnings, if any, of which the timing and amount are uncertain.

The Company adopted ASC Topic 740-10-05, Income Tax, which provides guidance for recognizing and measuring uncertain tax positions. It prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on derecognizing, classification and disclosure of these uncertain tax positions.

The Company’s policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense.

Capital Structure

The Company had 2,000,000,000 shares of common stock authorized, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of September 30, 2020, and December 31, 2019.

Earnings (loss) per share

Basic net income (loss) per share of common stock attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average shares of common stock outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying outstanding stock-based awards, warrants, options, or convertible debt using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net income (loss) per share of common stock attributable to common stockholders when their effect is dilutive.

Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive.

For the nine months ended September 30, 2020 and 2019, there were no potentially dilutive shares.

	For the nine months ended September 30,
	2020			2019
Statement of Operations Summary Information:
Net loss	$	(257,972	)	$	(190,766	)
Weighted-average common shares outstanding - basic and diluted		1,032,466,000			1,080,043,580
Net loss per share, basic and diluted	$	(0.00	)	$	(0.00	)

NOTE 2 – GOING CONCERN

During the quarter ended September 30, 2020, the Company was unable to generate cash flows sufficient to support its operations despite Kangzi’s business operation and was dependent on related party advances from the current controlling shareholder. In addition, the Company had experienced recurring net losses, and had an accumulated deficit of $19,156,356 and working capital deficit of $1,116,680 As of September 30, 2020. These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

In light of the impacts of the COVID-19 outbreak, if we are required to operate in a challenging economic environment in China, or incur unanticipated capital expenditures, or decide to accelerate growth, we may need additional financing. As of September 30, 2020, we had borrowed a loan from a shareholder for working capital purposes. The loan is unsecured, non-interest bearing and payable on demand. As of September 30, 2020, we have borrowed from such shareholder a total of $1,116,680 for working capital purposes. We cannot guarantee, however, that additional financing, if required, would be available on favorable terms, if at all. Such financing may include the use of additional debt or the sale of the Company’s equity interests. Any financing which involves the sale of the Company’s equity interests or instruments that are convertible into the Company’s equity interests could result in immediate and possibly significant dilution to our existing shareholders.

There can be no assurance that sufficient funds required during the next year or thereafter will be generated from any future operations or that funds will be available from external sources such as debt or equity financings or other potential sources. If the Company is unable to raise capital from external sources when required, there will be a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing stockholders. Management is now seeking an operating company with which to merge or acquire. In the foreseeable future, the Company will rely on related parties, such as its controlling shareholder, to provide advances to funds general corporate purposes and any potential acquisitions of profitable investments. There is no assurance, however, that the Company will achieve its objectives or goals.

NOTE 3 – CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of the following:

	As of September 30, 2020		As of December 31, 2019
Bank Deposits-China & HK		3,277		95,522
	$	3,277	$	95,522

NOTE 4 – OTHER RECEIVABLE

Other receivable consists of the following:

	As of September 30, 2020		As of December 31, 2019
Rental and POS machine deposits		14,588		14241
Others		50,058		61,494
Less: Allowance for doubtful accounts		-		(24,499	)
	$	64,646	$	51,236

Management periodically reviews account balance. If any indication occurs, the allowance for doubtful debts would be recognized. No such allowance has been recognized during the nine months ended September 30, 2020.

NOTE 5 – ADVANCES TO SUPPLIERS

Advances to suppliers consists of the following:

	As of September 30, 2020		As of December 31, 2019
Purchases of scientific research equipment		19,055		48,344
	$	19,055	$	48,344

NOTE 6 – INVENTORY

Inventory consists of the following:

	As of September 30, 2020		As of December 31, 2019
Working in process		434,437		421,533
Inventories - raw materials		47,001		-
	$	481,438	$	421,533

No impairment was provided for the inventories as of September 30, 2020 and December 31, 2019.

NOTE 7 – OPERATING LEASE RIGHT-OF-USE ASSET AND LIABILITIES

On September 1, 2019, the Company entered in a lease agreement for office space, the right-of-use asset is recognized as following:

	As of September 30, 2020		As of December 31, 2019
Operating lease right-of-use asset		147,712		202,976
	$	147,712	$	202,976

Operating lease liability consist both current and noncurrent component as the following:

	As of September 30, 2020			As of December 31, 2019
Operating lease liability - current portion		75,723			31,017
Operating lease liability		74,655			172,610
	$	150,378	)	$	203,627

	September 1, 2019
Weighted Average Remaining Lease Term(Year)		3
Weighted Average Discount Rate		4.75	%

The approximate future minimum lease payments under operating leases as:

	Operating Leases
Fiscal 2020		20,661
Fiscal 2021		83,533
Fiscal 2022		56,873
Total Lease payments		161,067
Less Imputed interest		10,689
Present value of lease liabilities	$	150,378

NOTE 8 – ADVANCES FROM CUSTOMERS

	As of September 30, 2020		As of December 31, 2019
Advances from customers⁽¹⁾		484,674		430,616
	$	484,674	$	430,616

⁽¹⁾

On October 15, 2019, JSEL entered into a clinical cooperation agreement (the “Clinical Cooperation Agreement”) with Shenzhen Saikun Biotechnology Co., Ltd. (“Saikun”). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of the Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month.

NOTE 9 – ACCRUED EXPENSES AND OTHER PAYABLES

Accrued expenses and other payables consist of the following:

	As of September 30, 2020		As of December 31, 2019
Accrued payroll		88,699		30,674
Other Payables		147,900		80,700
	$	236,599	$	111,374

Accrued payroll includes all company employee payroll liabilities as of September 30, 2020, and other payables contains employee reimbursements.

Operating lease liability consist both current and noncurrent component as the following:

	As of September 30, 2020		As of December 31, 2019
Operating lease liability - current portion		75,723		31,017
Operating lease liability		74,655		172,610
	$	150,378	$	203,627

NOTE 10 – RELATED PARTY TRANSACTIONS

As of September 30, 2020 and December 31, 2019, the Company owed related parties $898,344 and $874,749, respectively. As the Company has just started business activities in March 2019, all expenses incurred during this reporting period are paid by a shareholder, who is also a director of the Company. Expenses mainly included auditing, consulting and legal advisory expenses, government registration expenses, and payrolls.

NOTE 11 – EQUITY

The Company had not recorded any equity transactions during the nine months ended September 30, 2020.

The Company recorded the following equity transactions during the year ended December 31, 2019:

On March 15, 2019, the Company, with the approval of the Board, entered into a Share Cancellation Agreement (the “Share Cancellation Agreement”) with Mr. Ban Siong Ang, the President, Chief Executive Officer, and Chairman of the Board of the Company. Pursuant to the Share Cancellation Agreement, the Company and Mr. Ang agreed to cancel 109,006,861 shares of Common Stock previously issued to Mr. Ang.

NOTE 12 – INCOME TAXES

The Company is subject to U.S. Federal tax laws. The Company has not recognized an income tax benefit for its operating losses in the United States because the Company does not expect to commence active operations in the United States.

Heyu Healthcare Technology Limited was incorporated in Hong Kong and is subject to Hong Kong profits tax at a tax rate of 16.5%. Since Heyu Healthcare Technology Limited had no taxable income during the reporting period, it has not paid Hong Kong profits taxes. Heyu Healthcare Technology Limited has not recognized an income tax benefit for its operating losses in Hong Kong because the Company does not expect to commence active operations in Hong Kong.

The Company has been conducting and plans to continue to conduct its major operations in the PRC through JSEL in accordance with the relevant tax laws and regulations. The corporate income tax rate in China is 25%. The Company has not paid PRC profits taxes, since it had no taxable income during the reporting period.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of financial condition and results of operations relates to the operations and financial condition reported in our consolidated financial statements, which appear elsewhere in this Report, and should be read in conjunction with such financial statements and related notes included in this Report. Except for the historical information contained herein, the following discussion, as well as other information in this Report, contain “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the “safe harbor” created by those sections. Actual results and the timing of the events may differ materially from those contained in these forward-looking statements due to many factors, including those discussed in the “Forward-Looking Statements” set forth elsewhere in this Report.

Overview

Heyu Biological Technology Corporation (the “Company” or “we”) was incorporated in the state of Nevada on May 18, 1987, as Asphalt Associates, Inc. and changed its name to Pacific WebWorks in January 1999. From 1999 to 2016, the Company engaged in the development and distribution of web tools software, electronic business storefront hosting, and Internet payment systems for individuals and small to mid-sized businesses.

On July 3, 2018, the Company changed its name to Heyu Biological Technology Corporation and applied for a new ticker symbol HYBT.

On January 17, 2019, Jiashierle (Xiamen) Healthcare Technology Co., Ltd. (“JSEL”), a limited liability company organized under the laws of the People’s Republic of China (the “PRC”), and an indirect wholly owned subsidiary of the Company, entered into a Share Transfer Agreement (the “Share Transfer Agreement”) with Mr. Yu Xu (“Mr. Xu”), an individual who owned 90% of the equity interests of Shanghai Kangzi Medical Technology Co., Ltd., a limited liability company organized under the laws of the PRC (“Kangzi”). Pursuant to the Share Transfer Agreement, Mr. Xu transferred 60% of the equity interests of Kangzi to JSEL on January 17, 2019 for the purpose of developing a joint venture in the business of selling medical equipment. In return, JSEL would fund the operations of Kangzi in proportion to its equity interest in Kangzi. Kangzi owned no assets and conducts no business operation of its own. As a result, as of January 17, 2019, Kangzi became an indirect subsidiary of the Company.

Since the beginning of 2019, Mr. Xu has led the core research and development team of Kangzi to develop and manufacture a new medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the “Chamber”). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber. Specifically, we believe that exposure to an appropriate amount of submillimeter waves could accelerate the generation of a large number of cosmic ray muons inside the human body and that such cosmic ray muons could further facilitate cold nuclear fusion, which could reverse the process of cancer by converting selenium into nickel inside cells.

The core research and development team consists of researchers who have extensive experience in medicine and physics. The lead scientist of the team, Mr. Xu, served as the deputy chief engineer of the New Energy Base of the National Defense-Science and Technology Commission in 1995, the director of Shanghai Hengbian New Energy Research Institute from 2003 to 2008, and the chairman and chief scientist of Shanghai Guangzhui New Energy Technology Co., Ltd. from 2011 to 2019. In 2012, Mr. Xu was awarded the “Harmony Person of the Year in China” at the “2011 Harmony China Annual Summit” in Beijing. He was also jointly recognized as “Leaping China: One of the Most Influential People of the Year in 2011” by China International Economic and Technical Cooperation Promotion Association, China Elite Culture Promotion Association, and China Outstanding Chinese Merchants Association. In 2013, the Organizing Committee of Boau Forum on Asian Small and Medium Enterprise Development awarded Mr. Xu “2013 China Economic Outstanding Contribution Award.”

Pursuant to the terms of the Share Transfer Agreement, JSEL has the right to monitor and manage all aspects of operation of Kangzi, including its research and development activities relating to the Chamber. As the development of the Chamber enters its final stage at Kangzi, JSEL started accepting pre-orders for the Chamber in September 2019. On October 15, 2019, JSEL entered into a clinical cooperation agreement (the “Clinical Cooperation Agreement”) with Shenzhen Saikun Biotechnology Co., Ltd. (“Saikun”). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL RMB5.5 million as the total pre-order payment. RMB1.5 million and RMB1.5 million were delivered to JSEL on September 7 and September 27, 2019, respectively. The parties are currently working on the timing for payment of the remaining RMB2.5 million due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of a Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to Saikun’s preferred location, properly install it, and conduct a clinical trial that lasts at least one month. During the clinical trial, JSEL shall provide training sessions regarding the proper operation of the Chamber to Saikun’s employees. Both Saikun and JSEL are obligated to find third-party hospitals that will agree to act as partners to co-host the clinical trial and patients who will voluntarily undergo treatment provided by the Chamber. While Saikun is responsible for various expenses related to the clinical trial, JSEL is responsible for communicating with patients receiving treatment and other patient-related administrative matters. When JSEL determines that Saikun is capable of properly operating the Chamber and managing activities related to the Chamber, Saikun may request JSEL to move the Chamber to a location designated by Saikun and reinstall it. Furthermore, upon the successful completion of the clinical trial, JSEL shall provide Saikun governmental permits necessary for the operation of the Chamber, and Saikun shall operate the Chamber and provide related services to patients under the supervision of JSEL. In addition, JSEL shall transfer the right of using the Chamber and any beneficiary right affiliated with using the Chamber to Saikun upon receiving the full amount of payment from Saikun. JSEL, nevertheless, owns all the intellectual property rights affiliated with the Chamber. If the two parties decide to terminate the Clinical Cooperation Agreement prior to the expiration of its term, Saikun’s right of using the Chamber during the term is still effective as long as its use of the Chamber does not infringe any of JSEL’s intellectual property rights affiliated with the Chamber. The two parties agreed that the term of the Clinical Cooperation Agreement would not end until Kangzi successfully obtains permits issued by relevant government entities supervising development and sale of medical equipment.

To prepare for mass production of the Chambers, Kangzi is conducting clinical experiments to make further improvements on the Chamber and adjusting features of the mass-production mold for the Chambers. As its long-term business strategy, Kangzi focuses on researching, developing, and manufacturing high-technology medical equipment while targeting both individual and institutional customers. It plans to mass-produce the Chambers in small and medium sizes, establish operation centers to sell the Chambers in various cities across China, and initiate advertising and marketing campaigns on different media platforms. Kangzi will also monetize on services provided to customers who use the Chambers and other medical products. As of the date of this Report, we are still in the clinical experiment phase and Kangzi is still in the process of obtaining official governmental permits from relevant government authorities to produce and sell the Chambers on a national scale. There is no assurance that we will obtain the official governmental permits.

In addition to business activities related to the Chamber, the Company is also conducting research, development, manufacturing, and sale of healthcare equipment and plant-based disinfectant spray for treating skin infections and disinfecting wounds. On March 17, 2020, we entered into a business service cooperation agreement with Xiamen Qingda Intelligent Technology Co., Ltd., a wholly-owned subsidiary of Cross-strait Tsinghua Research Institute, pursuant to which the parties agreed to jointly improve a plant-based disinfectant spray for treating skin infections and disinfecting wounds. The term of such agreement is three years, and the agreement can be renewed upon mutual agreement of both parties. The original plant-based disinfectant spray was developed and owned by the Company, while the improved product shall be owned by both the Company and Cross-strait Tsinghua Research Institute. The Cross-strait Tsinghua Research Institute will receive 2% of the gross proceeds from sales of such improved product. By September 30, 2020, we had generated revenues of approximately $21,796 through sales of the improved product. In the near future, the Company aims to standardize the production and sale of healthcare equipment and plant-based disinfectant spray, while increasing its brand awareness in the healthcare markets.

The recent COVID-19 outbreak has spread throughout the world, especially in China, the United States, and Europe. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic—the first pandemic caused by a coronavirus. The outbreak has resulted in the implementation of significant governmental measures, including lockdowns, closures, quarantines, and travel bans, intended to control the spread of the virus, which measures have caused severe disruptions to our business operations. We suspended our business operation in early February 2020 due to government mandates and most of our staff members were forced to work from home. We partially resumed our business operations on February 17, 2020, and we fully resumed our business operations on March 1, 2020. However, as of the date of this Report, our management and scientists have been working remotely. Accordingly, our business, results of operations, and financial condition during the fiscal year ending December 31, 2020 have been adversely affected. As of the date of this Report, the COVID-19 outbreak seems to be under relative control in China and our management expects that our results of operations will improve in the coming fiscal quarter.

Liquidity and Capital Resources

As of September 30, 2020, we had assets of $743,555, which consisted of current assets of $3,277 in cash, $92,073 in other receivables, $19,055 as advances to suppliers, $481,438 as inventory, and noncurrent asset of $147,712 as operating lease right-of-use asset. We had liabilities of $1,787,178, which consisted of current liabilities of $17,152 in accounts payable, $236,599 in accrued expenses and other payables, $484,674 in advances from customers, $31 in taxes payable, $898,344 in related party payables, and $75,723 in short-term operating lease liabilities. We also had recognized long-term operating lease liabilities of $74,655 as noncurrent liabilities. We had an accumulated deficit of $19,156,356.

As of December 31, 2019, we had assets of $852,453, which mainly consisted of $95,522 in cash and cash equivalents, $421,533 in inventory, and $202,976 in operating lease right-of-use. As of December 31, 2019, we had liabilities of $1,620,394, which mainly consisted of $111,374 in accounts payable, $430,616 in advances from customers, $28 in other taxes payables, $874,749 in related party payables, and $172,610 in operating lease liabilities. We also had an accumulated deficit of $18,909,705. Since we started our business operations in March 2019, our director, Mr. Hungseng Tan, has been advancing the Company’s daily operating expenses.

In light of the impacts of the COVID-19 outbreak, if the economic environment in China worsens, or if we incur unanticipated capital expenditures or decide to accelerate growth, we may need additional financing. As of September 30, 2020, we had borrowed a total of $898,344 from a stockholder for working capital purposes. The loan is unsecured, non-interest bearing, and payable on demand. We cannot guarantee, however, that additional financing, if required, would be available on favorable terms, if at all. Such financing may include the use of additional debt or the sale of the Company’s equity interests. Any financing which involves the sale of the Company’s equity interests or instruments that are convertible into the Company’s equity interests could result in immediate and possibly significant dilution to our existing stockholders.

Results of Operations

From December 28, 2016 to September 6, 2019, we were a shell company without any substantive assets or operations. Since September 7, 2019, we have ceased to be a shell company and adopted the business of Kangzi, receiving our first pre-order payment from Saikun. For a more detailed description, please see “Overview” above.

Comparison of the Three Months Ended September 30, 2020 and 2019

Our revenues during the three months ended September 30, 2020, were $16,600, and cost of revenues was $5,543, as compared to revenues of $7,387 and cost of revenues $3,666 for the same period in 2019, respectively. The increase in our revenue were mainly due to adjustment of our product line in reaction to the COVID-19 outbreak.. On March 17, 2020, we entered into a business service cooperation agreement with Xiamen Qingda Intelligent Technology Co., Ltd., pursuant to which we agreed to jointly improve the plant-based disinfectant spray for treating skin infections and disinfecting wounds. By September 30, 2020, we had generated revenues of approximately $21,796 through sales of the improved product. We have experienced significant growth in sales during the fiscal quarter ended September 30, 2020, as compared to that of the fiscal quarter ended June 30, 2020. Our management believes that our revenues will keep growing in the upcoming fiscal quarters.

We had incurred selling expenses of $301 and administrative expenses of $88,037 during the three months ended September 30, 2020, as compared to $5,992 and $202,505 for the same period in 2019, respectively. The decrease in selling expenses was mainly due to fewer sales activities for the our new products in the quarter ended September 30, 2020 compared with the same period in 2019, selling expenses. The decrease in administrative expenses was mainly due to decreased office rental expenses and employment expenses during the period. We might incur operating expenses without sufficient revenues, as we determined to focus on the research, development, and manufacturing of healthcare equipment and products. We will depend upon our officers and directors to make loans to the Company to meet any costs that may occur. All such advances will be interest-free loans or equity contributions. By the end of September 2019, we have received customer prepayments for our new medical product and services pursuant to the Clinical Cooperation Agreement. When we start fulfilling our obligations under the Clinical Cooperation Agreement, we expect to see significant increase in revenues. As of the date of this Report, we have yet to fulfill our obligations under the agreement.

Comparison of the Nine Months Ended September 30, 2020 and 2019

Our revenues during the nine months ended September 30, 2020, were $52,383, and the cost of revenues was $22,732, as compared to $49,930 and $28,272 for the same period in 2019, respectively. The increases in revenues and cost of revenues were due to an adjustment of product line based on the impact of the COVID-19 outbreak. As our prospective customers’ businesses had been adversely affected by the COVID-19 outbreak, the demand for our main products and services decreased. Moreover, as of September 30, 2020, our sales and marketing team could not implement offline sales and marketing strategies as originally planned due to the COVID-19 outbreak. As a result, we were unable to secure the same amount of new revenue sources during the nine months ended September 30, 2020 as compared to the same period in 2019. On March 17, 2020, we entered into a business service cooperation agreement with Xiamen Qingda Intelligent Technology Co., Ltd., pursuant to which we agreed to jointly improve the plant-based disinfectant spray for treating skin infections and disinfecting wounds. By September 30, 2020, we had generated revenues of approximately $21,796 through sales of the improved product. As of the date of this Report, the COVID-19 outbreak seems to be under relative control in China. We believe that the impact of the COVID-19 outbreak on our business is both temporary and limited, and our revenues will start growing again as we resume our business activities.

We had incurred selling expenses of $6,527 and administrative expenses of $280,134 during the nine months ended September 30, 2020, as compared to $1,385 and $209,702 for the same period in 2019, respectively. The increase in selling expenses was mainly due to the launch of sales of the Company’s improved plant-based disinfectant spray during the period. The increase in administrative expenses was mainly due to increased consulting expenses during the period. We might incur operating expenses without sufficient revenues, as we have recently determined to focus on the research, development, and manufacturing of healthcare equipment and products. We will depend upon our officers and directors to make loans to the Company to meet any costs that may occur. All such advances will be interest-free loans or equity contributions. However, by the end of September 2019, we have received customer prepayments for our new medical product and services pursuant to the Clinical Cooperation Agreement. When we start fulfilling our obligations under the Clinical Cooperation Agreement, we expect to see significant increase in revenues. As of the date of this Report, we have yet to fulfill our obligations under the agreement.

Going Concern

The accompanying financial statements are presented on a going concern basis. The Company’s financial condition raises substantial doubt about the Company’s ability to continue as a going concern. As of September 30, 2020, the Company had an accumulated deficit of $19,156,356, and a net loss of $77,612 and $257,972 for the three and nine months ended September 30, 2020, respectively. It is relying on advances from its director, Mr. Hungseng Tan, to meet its limited operating expenses.

In light of the impacts of the COVID-19 outbreak, if the economic environment in China worsens, or if we incur unanticipated capital expenditures or decide to accelerate growth, we may need additional financing. As of September 30, 2020, we had borrowed a loan from a stockholder for working capital purposes. The loan is unsecured, non-interest bearing and payable on demand. We cannot guarantee, however, that additional financing, if required, would be available on favorable terms, if at all. Such financing may include the use of additional debt or the sale of the Company’s equity interests. Any financing which involves the sale of the Company’s equity interests or instruments that are convertible into the Company’s equity interests could result in immediate and possibly significant dilution to our existing stockholders.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues, or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

ITEM 3 QUANTITATIVE AND QUALITATIVE ABOUT MATERIAL RISKS

Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Management has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this Report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were not effective as a result of a material weakness primarily related to a lack of a sufficient number of personnel with appropriate training and experience in accounting principles generally accepted in the United States of America, or U.S. GAAP. To remediate the material weakness, our Chief Financial Officer, as a member of CPA Australia, hence a Certified Public Accountant in Australia, has attended professional trainings regarding applying U.S. GAAP on a regular basis. In the near future, we also intend to hire more personnel with sufficient training and experience in U.S. GAAP.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarterly period ended September 30, 2020, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any company have been detected.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. There are currently no legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition, or operating results.

ITEM 1A. RISK FACTORS

Smaller reporting companies are not required to provide the information required by this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

There were no unregistered sales of equity securities during the period covered by this Report.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. – EXHIBITS

Exhibit		Exhibit Description
3.1⁽¹⁾		Articles of Incorporation.
3.2⁽²⁾		Certificate of Amendment.
3.3⁽³⁾		Certificate of Amendment.
3.4⁽⁴⁾		Certificate of Amendment.
3.5⁽⁵⁾		By-Laws.
3.6⁽⁶⁾		First Amendment to the By-Laws.
3.7⁽⁷⁾		Second Amendment to the By-Laws.
31.1*		Certification pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*		XBRL Instance Document
101.SCH*		XBRL Taxonomy Extension Schema Linkbase
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase
101.DEF*		XBRL Taxonomy Extension Definition Linkbase
101.LAB*		XBRL Taxonomy Extension Label Linkbase
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase

(1)	Filed as an exhibit to the Company’s Registration Statement on Form 10-12G, as filed with the SEC on July 16, 1999, and incorporated herein by this reference.
(2)	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on July 6, 2018, and incorporated herein by reference.
(3)	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on August 3, 2018, and incorporated herein by reference.
(4)	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on September 14, 2018, and incorporated herein by reference.
(5)	Filed as an exhibit to the Company’s Registration Statement on Form 10-12G, as filed with the SEC on July 16, 1999, and incorporated herein by this reference.
(6)	Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q, as filed with the SEC on November 13, 2018, and incorporated herein by this reference.
(7)	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on July 1, 2019, and incorporated herein by reference.

Filed herewith.

In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 34-47986, the certifications furnished in Exhibits 32.1 and 32.2 herewith are deemed to accompany this Form 10-Q and will not be deemed filed for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	Heyu Biological Technology Corporation

Dated: November 16, 2020	By:	/s/ Ban Siong Ang
	Name:	Ban Siong Ang
	Title:	Chief Executive Officer


Dated: November 16, 2020	By:	/s/ Wendy Li
	Name:	Wendy Li
	Title:	Chief Financial Officer

EX-31.1 2 f10q0920ex31-1_heyubio.htm CERTIFICATION

Exhibit 31.1

Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and
15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Ban Siong Ang, certify that:

	1.	I have reviewed this quarterly report on Form 10-Q of Heyu Biological Technology Corporation;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

	4.	The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

	Date:	November 16, 2020

		/s/ Ban Siong Ang
	Name:	Ban Siong Ang
	Title:	Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 f10q0920ex31-2_heyubio.htm CERTIFICATION

Exhibit 31.2

Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and
15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Wendy Li, certify that:

	1.	I have reviewed this quarterly report on Form 10-Q of Heyu Biological Technology Corporation;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

	4.	The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

	Date:	November 16, 2020

		/s/ Wendy Li
	Name:	Wendy Li
	Title:	Chief Financial Officer (Principal Financial Officer)

EX-32.1 4 f10q0920ex32-1_heyubio.htm CERTIFICATION

Exhibit 32.1

Certification by the Principal Executive Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), I, Ban Siong Ang, Chief Executive Officer of Heyu Biological Technology Corporation (the “Company”), hereby certify to my knowledge that:

The quarterly report on Form 10-Q for the quarter ended September 30, 2020 of the Company fully complies, in all material respects, with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 16, 2020

/s/ Ban Siong Ang

Ban Siong Ang

Chief Executive Officer

(Principal Executive Officer)

EX-32.2 5 f10q0920ex32-2_heyubio.htm CERTIFICATION

Exhibit 32.2

Certification by the Principal Financial Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), I, Wendy Li, Chief Financial Officer of Heyu Biological Technology Corporation (the “Company”), hereby certify to my knowledge that:

The quarterly report on Form 10-Q for the quarter ended September 30, 2020 of the Company fully complies, in all material respects, with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 16, 2020

/s/ Wendy Li

Wendy Li

Chief Financial Officer

(Principal Financial Officer)

EX-101.INS 6 hybt-20200930.xml XBRL INSTANCE FILE 0001086303 2020-01-01 2020-09-30 0001086303 2020-11-13 0001086303 2020-09-30 0001086303 2019-12-31 0001086303 2020-07-01 2020-09-30 0001086303 2019-07-01 2019-09-30 0001086303 2019-01-01 2019-09-30 0001086303 2018-12-31 0001086303 2019-09-30 0001086303 srt:ParentCompanyMember us-gaap:CommonStockMember 2018-12-31 0001086303 srt:ParentCompanyMember hybt:SharesToBeCancelledMember 2018-12-31 0001086303 srt:ParentCompanyMember us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001086303 srt:ParentCompanyMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001086303 srt:ParentCompanyMember us-gaap:RetainedEarningsMember 2018-12-31 0001086303 us-gaap:NoncontrollingInterestMember 2018-12-31 0001086303 srt:ParentCompanyMember us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001086303 srt:ParentCompanyMember hybt:SharesToBeCancelledMember 2019-01-01 2019-09-30 0001086303 srt:ParentCompanyMember us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001086303 srt:ParentCompanyMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001086303 srt:ParentCompanyMember us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001086303 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-09-30 0001086303 srt:ParentCompanyMember us-gaap:CommonStockMember 2019-09-30 0001086303 srt:ParentCompanyMember hybt:SharesToBeCancelledMember 2019-09-30 0001086303 srt:ParentCompanyMember us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001086303 srt:ParentCompanyMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001086303 srt:ParentCompanyMember us-gaap:RetainedEarningsMember 2019-09-30 0001086303 us-gaap:NoncontrollingInterestMember 2019-09-30 0001086303 srt:ParentCompanyMember us-gaap:CommonStockMember 2019-12-31 0001086303 srt:ParentCompanyMember us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001086303 srt:ParentCompanyMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001086303 srt:ParentCompanyMember us-gaap:RetainedEarningsMember 2019-12-31 0001086303 us-gaap:NoncontrollingInterestMember 2019-12-31 0001086303 srt:ParentCompanyMember us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001086303 srt:ParentCompanyMember hybt:SharesToBeCancelledMember 2020-01-01 2020-09-30 0001086303 srt:ParentCompanyMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001086303 srt:ParentCompanyMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001086303 srt:ParentCompanyMember us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001086303 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-09-30 0001086303 srt:ParentCompanyMember us-gaap:CommonStockMember 2020-09-30 0001086303 srt:ParentCompanyMember hybt:SharesToBeCancelledMember 2020-09-30 0001086303 srt:ParentCompanyMember us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001086303 srt:ParentCompanyMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001086303 srt:ParentCompanyMember us-gaap:RetainedEarningsMember 2020-09-30 0001086303 us-gaap:NoncontrollingInterestMember 2020-09-30 0001086303 hybt:SharePurchaseAgreementMember 2018-04-02 2018-04-18 0001086303 hybt:SharePurchaseAgreementMember 2018-04-18 0001086303 hybt:ShanghaiKangziMedicalTechnologyCoLtdMember 2019-01-17 0001086303 hybt:JSELMember 2019-01-17 0001086303 2020-03-17 0001086303 2019-09-01 0001086303 hybt:HPTechnologyLimitedMember 2020-01-01 2020-09-30 0001086303 hybt:HeyuHealthcareTechnologyLimitedMember 2020-01-01 2020-09-30 0001086303 hybt:JSELMember 2020-01-01 2020-09-30 0001086303 hybt:KangziMember 2020-01-01 2020-09-30 0001086303 hybt:BankDepositsChinaAndHKMember 2020-09-30 0001086303 hybt:BankDepositsChinaAndHKMember 2019-12-31 0001086303 srt:OtherPropertyMember 2020-09-30 0001086303 srt:OtherPropertyMember 2019-12-31 0001086303 hybt:RightsOfUseLiabilityMember 2020-09-30 0001086303 hybt:RightsOfUseLiabilityMember 2019-12-31 0001086303 2019-10-01 2019-10-15 0001086303 hybt:OperatingLeaseLiabilityMember 2020-09-30 0001086303 hybt:OperatingLeaseLiabilityMember 2019-12-31 0001086303 hybt:ShareCancellationAgreementMember 2019-03-15 0001086303 hybt:HKMember 2020-01-01 2020-09-30 0001086303 pf0:CN 2020-01-01 2020-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure On October 15, 2019, JSEL entered into a clinical cooperation agreement (the “Clinical Cooperation Agreement”) with Shenzhen Saikun Biotechnology Co., Ltd. (“Saikun”). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of the Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month. false --12-31 Q3 2020 2020-09-30 10-Q 0001086303 Yes false 000-26731 Non-accelerated Filer NV Yes Heyu Biological Technology Corp false true 1032466000

3277

95522

32842

64646 51236

27427

19055

48344

481438

421533

595843

649477

147712

202976

147712

202976

743555

852453

17152

80700

236599

30674

484674

430616

75723

31017

898344

874749

1712523

1447784

74655

172610

74655

172610

1787178

1620394

1032466

17149050

-6493

12319

-19156356

-18909705

-981333

-715870

-62290

-52071

-1043623

-767941

743555

852453

0.001

2000000000

1032466000

16600

7387

52383

49930

5543

3666

22732

28272

11057

3721

29651

21658

301 5992 6527 1385

88037

202505

280134

209702

88338

208497

286661

211087

-77281

-204776

-257010

-189429

-331

-370

-962

-1337

-77612

-205146

-257972

-190766

-77612

-205146

-257972

-190766

-2407

-20455

-11321

-18242

-75205

-184691

-246651

-172524

24912

-12506

19913

-3418

-100117

-172185

-266564

-169106

-2339

1320

-1101

226

-97778

-173505

-265463

-169332

0.00

1032466000

1019289346

1032466000

1080043580

-32842

13410

3242

27427

-29289 81431

59905

311134

-55264 209587

-63548

95090

205925

-54058 -420406

-1

53249 -209798

-98130

-276014

23596

677945

23596

677945

-17711

12832

-92245

414763

37555

452318

1141472861

1141473

-109007

17149050

2567

-18421319

-237236

-109006861

-109007

109007

14378 -1546 12832

-357216

-38697

1032466000

1032466

17149050

16945

-18778535

-40243

-620317

1032466000

1032466

17149050

12319

-18909705

-52071

-18812 1101 -17711

-246651

-11320

1032466000

1032466

17149050

-6493

-19156356

-62290

NOTE 1 – THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES Heyu Biological Technology Corporation (the “Company”) was incorporated in the state of Nevada on May 18, 1987, as Asphalt Associates, Inc. and changed its name to Pacific WebWorks in January 1999. From 1999 to 2016 the Company engaged in the development and distribution of web tools software, electronic business storefront hosting, and Internet payment systems for individuals and small to mid-sized businesses. On February 23, 2016, the Company filed a voluntary petition for bankruptcy in the U.S. Bankruptcy Court for the District of Utah, and soon afterwards ceased its business activities. On August 19, 2016, the Company proposed a plan of liquidation and on November 28, 2016, the court entered an order confirming the plan of liquidation and establishing a liquidating trust. On December 28, 2016, all assets and liabilities of the Company were transferred to the liquidating trust. On April 18, 2018, the Company entered into a share purchase agreement with Mr. Ban Siong Ang and Mr. Dan Masters (the “Share Purchase Agreement”), pursuant to which Mr. Ang acquired 1,021,051,700 shares, representing 98.91% of the issued and outstanding shares of common stock of the Company (“Common Stock”), from Mr. Masters for an aggregate purchase price of $335,000 (the “Share Purchase”). As a result of the Share Purchase, Dan Masters resigned from his positions as the President, Chief Executive Officer, Chief Financial Officer, Secretary and Chairman of the Board of the Company. Such resignations took place in connection with the closing of the Share Purchase and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Additionally, all debt due to Mr. Masters from the Company was cancelled as of the closing of the Share Purchase and recognized as contributed capital. On April 18, 2018, to fill the vacancies created by Mr. Masters’ resignation, Ban Siong Ang and Hung Seng Tan were elected as the directors of the Company. Mr. Ang was appointed as President, Chief Executive Officer, and Chairman of the Board of the Company. Mr. Tan was appointed as the Executive Director of the Company. Ms. Wendy Li was appointed as the Chief Financial Officer of the Company. On July 3, 2018, the Company changed its name to Heyu Biological Technology Corporation and applied for a new ticker symbol “HYBT”. During 2018, the Company established the following subsidiaries: (1) HP Technology Limited, a British Virgin Islands business company incorporated on September 20, 2018, and (2) Heyu Healthcare Technology Limited, a Hong Kong company incorporated on March 29, 2018. On November 5, 2018, the Company acquired the following subsidiary: Jiashierle (Xiamen) Healthcare Technology Co., Ltd. (“JSEL”), a limited liability company incorporated under the laws of the People’s Republic of China (the “PRC”) on November 16, 2017. On January 17, 2019, JSEL entered into a share transfer agreement (the “Share Transfer Agreement”) with Mr. Yu Xu (“Mr. Xu”), an individual with an address at No. 68 Chengde South Road, Qingpu District, Huaian City, Jiangsu Province, the PRC. Mr. Xu owned 90% of the equity interests of Shanghai Kangzi Medical Technology Co., Ltd., a limited liability company organized under the laws of the PRC (“Kangzi”). JSEL received 60% of the outstanding equity interest of Kangzi from Mr. Xu for the purpose of developing a joint venture in selling medical equipment. It was Mr. Xu and JSEL’s intention that JSEL would fund the operations of Kangzi in proportion to JSEL’s equity interest in Kangzi. At the time of the share transfer, Kangzi owned no assets and conducted no business operation. Since the beginning of 2019, Mr. Xu has led the core research and development team of Kangzi to develop and manufacture a new medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the “Chamber”). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber. We believe that exposure to an appropriate amount of submillimeter waves would accelerate the generation of a large number of cosmic ray muons inside the human body and that such cosmic ray muons could further facilitate cold nuclear fusion, which could reverse the cancer by converting selenium into nickel inside cells. Our team consists of researchers who have years of extensive experience in medicine and physics. The lead scientist of the team, Mr. Xu, had extensive professional experience in the aforementioned fields and has served as the deputy chief engineer of the New Energy Base of the National Defense-Science and Technology Commission in 1995, the chairman and chief scientist of Shanghai Guangzhui New Energy Technology Co., Ltd. from 2011 to 2019, and the director of Shanghai Hengbian New Energy Research Institute from 2003 to 2008. In 2012, Mr. Xu received the “Harmony-Person of the Year in China” award at the “2011 Harmony China Annual Summit” in Beijing. He was recognized as “Leaping China: One of the Most Influential People of the Year in 2011” by China International Economic and Technical Cooperation Promotion Association, China Elite Culture Promotion Association, and China Outstanding Chinese Merchants Association. Mr. Xu also received the “2013 China Economic Outstanding Contribution Award” from the Organizing Committee of Boau Forum on Asian SME Development. Pursuant to the terms of the share transfer agreement entered into by JSEL and Kangzi on January 17, 2019, JSEL has the right to monitor and manage all aspects of operation of Kangzi, including its research and development activities relating to the Chamber. As the development of the Chamber enters its final stage, JSEL started accepting pre-orders for the Chamber in September 2019. The outbreak of the novel coronavirus, commonly referred to as “COVID-19”, first found in mainland China, then in Asia and eventually throughout the world, has significantly affected business and manufacturing activities within China, including travel restrictions, widespread mandatory quarantines, and suspension of business activities within China. These measures have caused substantial disruptions to our business operations. We suspended our business operation in early February 2020 due to government mandates. We partially recovered our business operation on February 17, 2020, and on March 1, 2020, most of our staff members returned to the office and we fully resumed our business operations on the same day. Accordingly, our business, results of operations and financial condition were adversely affected. As of the date of this Report, Chinese industries have gradually resumed businesses as government officials started to ease the restrictive measures since April 2020. However, as most of our top management team is an overseas team, due to the international travel ban, we still operate under remote-working conditions, so the business of the Company is still recovering. Our management believes that our revenues will gradually improve as the epidemic and the travel ban are lifted. On March 17, 2020, we entered into a business service cooperation agreement with Xiamen Qingda Intelligent Technology Co., Ltd., a wholly-owned subsidiary of Cross-strait Tsinghua Research Institute, pursuant to which we agreed to jointly improve the plant based disinfectant spray for treating skin infections and disinfecting wounds. The term of such agreement is three years, and can be renewed upon mutual agreement of both parties. The original plant based disinfectant spray was developed and owned by the Company, while the improved product shall be owned by both the Company and the Cross-strait Tsinghua Research Institute. The Cross-strait Tsinghua Research Institute will receive 2% of gross proceeds from the sales of such improved product. By September 30, 2020, we have had generated revenues of approximately $21,796 through sales of the improved product. Basis of Presentation The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The condensed consolidated financial statements of the Company as of and for the three and nine months ended September 30, 2020 and 2019 are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) that have been made are necessary to fairly present the financial position of the Company As of September 30, 2020, the results of its operations for the three and nine months ended September 30, 2020 and 2019, and its cash flows for the nine months ended September 30, 2020 and 2019. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The balance sheet as of December 31, 2019 has been derived from the Company’s audited financial statements included in the Form 10-K for the year ended December 31, 2019.  The statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the financial statements and other information included in the Company’s Annual Report on Form 10-K as filed with the SEC for the fiscal year ended December 31, 2019. As of September 30, 2020, the details of the consolidating subsidiaries are as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Company</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">Jurisdiction of Formation</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">Attributable equity interest %</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%; text-align: left">HP Technology Limited</td><td style="width: 1%"> </td> <td style="width: 22%; text-align: center; padding-left: 5.4pt">British Virgin Islands</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Heyu Healthcare Technology Limited</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">Hong Kong</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>JSEL</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Kangzi</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left">%</td></tr> </table> Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however, actual results could differ from these estimates. Significant estimates include the allowance for doubtful accounts, impairment assessments of goodwill, valuation of deferred tax assets, rebilling collections and certain accrued liabilities such as contingent liabilities. As of September 30, 2020, the Company considered the economic implications of the COVID-19 pandemic on its significant judgments and estimates. Given the impact and other unforeseen effects on the global economy from the COVID-19 pandemic, these estimates required increased judgment, and actual results could differ from these estimates. Cash Equivalents The Company considers all highly liquid debt instruments purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying unaudited condensed consolidated balance sheets for cash and cash equivalents approximate their fair value. All of the Company’s cash that is held in bank accounts in the PRC and Hong Kong is not protected by Federal Deposit Insurance Corporation (“FDIC”) insurance or any other similar insurance in the PRC, or Hong Kong. Accounts receivable and allowance for doubtful accounts Accounts receivable are stated at the historical carrying amount net of allowance for doubtful accounts. The Company maintains an allowance for doubtful accounts which reflects its best estimate of amounts that potentially will not be collected. The Company determines the allowance for doubtful accounts taking into consideration various factors, including but not limited to historical collection experience and credit-worthiness of the debtors, as well as the age of the individual receivables balance. Additionally, the Company makes specific bad debt provisions based on any specific knowledge the Company has acquired that might indicate that an account is uncollectible. The facts and circumstances of each account may require the Company to use substantial judgment in assessing its collectability. Inventories Inventories consist of finished goods, work in process, and raw materials. Inventories are stated at the lower of cost or market value. The Company applies the weighted average cost method to its inventory. Leases The Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which supersedes the lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. Operating leases are included in operating lease right-of-use (“ROU”) assets and short-term and long-term lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, we use the industry incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Adoption of the standard resulted in the initial recognition of $215,298 of ROU assets and $215,298 of lease liabilities on our consolidated balance sheet related to office space lease commitment on September 1, 2019. ASU 2016-02 requires that public companies use a secured incremental browning rate for the present value of lease payments when the rate implicit in the contract is not readily determinable. We determine a secured rate on a quarterly basis and update the weighted average discount rate accordingly. Lease terms and discount rate follow. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 1, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Weighted Average Remaining Lease Term(Year)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.75</td><td style="text-align: left">%</td></tr> </table> The approximate future minimum lease payments under operating leases as: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Fiscal 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">20,661</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Fiscal 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Fiscal 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,873</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Total Lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161,067</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,689</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150,378</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> Foreign Currency For fiscal year 2020, the Company’s principal country of operations is the PRC. The accompanying consolidated financial statements are presented in US$. The functional currency of the Company is US$, and the functional currency of the Company’s subsidiaries is RMB. The consolidated financial statements are translated into US$ from RMB at year-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transactions occurred. The resulting translation adjustments are recorded as a component of shareholders’ equity included in other comprehensive income. Gains and losses from foreign currency transactions are included in profit or loss. There were no gains and losses from foreign currency transactions during the quarters ended September 30, 2020 and 2019. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8013</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.9668</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.9941</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8618</td><td style="width: 1%; text-align: left"> </td></tr> </table> The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation. General and administrative costs General and administrative expenses include personnel expenses for executive, finance, and internal support personnel. In addition, general and administrative expenses include fees for bad debt costs, professional legal and accounting services, insurance, office space, banking and merchant fees, and other overhead-related costs. Income Taxes The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes. Income taxes are provided on an asset and liability approach for financial accounting and reporting of income taxes. Any tax paid by subsidiaries during the year is recorded. Current tax is based on the profit or loss from ordinary activities adjusted for items that are non-assessable or disallowable for income tax purpose and is calculated using tax rates that have been enacted or substantively enacted at the balance sheet date. ASC Topic 740 also requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carry-forwards. ASC Topic 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets, including those related to the U.S. net operating loss carry-forwards, are dependent upon future earnings, if any, of which the timing and amount are uncertain. The Company adopted ASC Topic 740-10-05, Income Tax, which provides guidance for recognizing and measuring uncertain tax positions. It prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on derecognizing, classification and disclosure of these uncertain tax positions. The Company’s policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense. Capital Structure The Company had 2,000,000,000 shares of common stock authorized, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of September 30, 2020, and December 31, 2019. Earnings (loss) per share Basic net income (loss) per share of common stock attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average shares of common stock outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying outstanding stock-based awards, warrants, options, or convertible debt using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net income (loss) per share of common stock attributable to common stockholders when their effect is dilutive. Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive. For the nine months ended September 30, 2020 and 2019, there were no potentially dilutive shares. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Statement of Operations Summary Information:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(257,972</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(190,766</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Weighted-average common shares outstanding - basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,032,466,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,080,043,580</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table>

1021051700

0.9891

335000

0.90

0.60

0.02 21796

Basis of Presentation The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The condensed consolidated financial statements of the Company as of and for the three and nine months ended September 30, 2020 and 2019 are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) that have been made are necessary to fairly present the financial position of the Company As of September 30, 2020, the results of its operations for the three and nine months ended September 30, 2020 and 2019, and its cash flows for the nine months ended September 30, 2020 and 2019. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The balance sheet as of December 31, 2019 has been derived from the Company’s audited financial statements included in the Form 10-K for the year ended December 31, 2019.  The statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the financial statements and other information included in the Company’s Annual Report on Form 10-K as filed with the SEC for the fiscal year ended December 31, 2019. As of September 30, 2020, the details of the consolidating subsidiaries are as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Company</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">Jurisdiction of Formation</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">Attributable equity interest %</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%; text-align: left">HP Technology Limited</td><td style="width: 1%"> </td> <td style="width: 22%; text-align: center; padding-left: 5.4pt">British Virgin Islands</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Heyu Healthcare Technology Limited</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">Hong Kong</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>JSEL</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Kangzi</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left">%</td></tr> </table>

Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however, actual results could differ from these estimates. Significant estimates include the allowance for doubtful accounts, impairment assessments of goodwill, valuation of deferred tax assets, rebilling collections and certain accrued liabilities such as contingent liabilities. As of September 30, 2020, the Company considered the economic implications of the COVID-19 pandemic on its significant judgments and estimates. Given the impact and other unforeseen effects on the global economy from the COVID-19 pandemic, these estimates required increased judgment, and actual results could differ from these estimates.

Cash Equivalents The Company considers all highly liquid debt instruments purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying unaudited condensed consolidated balance sheets for cash and cash equivalents approximate their fair value. All of the Company’s cash that is held in bank accounts in the PRC and Hong Kong is not protected by Federal Deposit Insurance Corporation (“FDIC”) insurance or any other similar insurance in the PRC, or Hong Kong.

Accounts receivable and allowance for doubtful accounts Accounts receivable are stated at the historical carrying amount net of allowance for doubtful accounts. The Company maintains an allowance for doubtful accounts which reflects its best estimate of amounts that potentially will not be collected. The Company determines the allowance for doubtful accounts taking into consideration various factors, including but not limited to historical collection experience and credit-worthiness of the debtors, as well as the age of the individual receivables balance. Additionally, the Company makes specific bad debt provisions based on any specific knowledge the Company has acquired that might indicate that an account is uncollectible. The facts and circumstances of each account may require the Company to use substantial judgment in assessing its collectability.

Inventories Inventories consist of finished goods, work in process, and raw materials. Inventories are stated at the lower of cost or market value. The Company applies the weighted average cost method to its inventory.

Leases The Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which supersedes the lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. Operating leases are included in operating lease right-of-use (“ROU”) assets and short-term and long-term lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, we use the industry incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Adoption of the standard resulted in the initial recognition of $215,298 of ROU assets and $215,298 of lease liabilities on our consolidated balance sheet related to office space lease commitment on September 1, 2019. ASU 2016-02 requires that public companies use a secured incremental browning rate for the present value of lease payments when the rate implicit in the contract is not readily determinable. We determine a secured rate on a quarterly basis and update the weighted average discount rate accordingly. Lease terms and discount rate follow. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 1, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Weighted Average Remaining Lease Term(Year)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.75</td><td style="text-align: left">%</td></tr> </table> The approximate future minimum lease payments under operating leases as: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Fiscal 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">20,661</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Fiscal 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Fiscal 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,873</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Total Lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161,067</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,689</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150,378</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

215298 215298

Foreign Currency For fiscal year 2020, the Company’s principal country of operations is the PRC. The accompanying consolidated financial statements are presented in US$. The functional currency of the Company is US$, and the functional currency of the Company’s subsidiaries is RMB. The consolidated financial statements are translated into US$ from RMB at year-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transactions occurred. The resulting translation adjustments are recorded as a component of shareholders’ equity included in other comprehensive income. Gains and losses from foreign currency transactions are included in profit or loss. There were no gains and losses from foreign currency transactions during the quarters ended September 30, 2020 and 2019. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8013</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.9668</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.9941</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8618</td><td style="width: 1%; text-align: left"> </td></tr> </table> The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.

General and administrative costs General and administrative expenses include personnel expenses for executive, finance, and internal support personnel. In addition, general and administrative expenses include fees for bad debt costs, professional legal and accounting services, insurance, office space, banking and merchant fees, and other overhead-related costs.

Income Taxes The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes. Income taxes are provided on an asset and liability approach for financial accounting and reporting of income taxes. Any tax paid by subsidiaries during the year is recorded. Current tax is based on the profit or loss from ordinary activities adjusted for items that are non-assessable or disallowable for income tax purpose and is calculated using tax rates that have been enacted or substantively enacted at the balance sheet date. ASC Topic 740 also requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carry-forwards. ASC Topic 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets, including those related to the U.S. net operating loss carry-forwards, are dependent upon future earnings, if any, of which the timing and amount are uncertain. The Company adopted ASC Topic 740-10-05, Income Tax, which provides guidance for recognizing and measuring uncertain tax positions. It prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on derecognizing, classification and disclosure of these uncertain tax positions. The Company’s policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense.

Capital Structure The Company had 2,000,000,000 shares of common stock authorized, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of September 30, 2020, and December 31, 2019.

1032466000 1032466000

Earnings (loss) per share Basic net income (loss) per share of common stock attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average shares of common stock outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying outstanding stock-based awards, warrants, options, or convertible debt using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net income (loss) per share of common stock attributable to common stockholders when their effect is dilutive. Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive. For the nine months ended September 30, 2020 and 2019, there were no potentially dilutive shares. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Statement of Operations Summary Information:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(257,972</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(190,766</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Weighted-average common shares outstanding - basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,032,466,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,080,043,580</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Company</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">Jurisdiction of Formation</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">Attributable equity interest %</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%; text-align: left">HP Technology Limited</td><td style="width: 1%"> </td> <td style="width: 22%; text-align: center; padding-left: 5.4pt">British Virgin Islands</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Heyu Healthcare Technology Limited</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">Hong Kong</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>JSEL</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Kangzi</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left">%</td></tr> </table> HP Technology Limited

British Virgin Islands

1.00

Heyu Healthcare Technology Limited

Hong Kong

1.00

JSEL

PRC

1.00

Kangzi

PRC

0.60

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 1, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Weighted Average Remaining Lease Term(Year)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.75</td><td style="text-align: left">%</td></tr> </table>

P3Y

0.0475

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Fiscal 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">20,661</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Fiscal 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Fiscal 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,873</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Total Lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161,067</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,689</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150,378</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

20661

83533

56873

161067

10689

150378 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8013</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.9668</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.9941</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8618</td><td style="width: 1%; text-align: left"> </td></tr> </table>

6.8013

6.9668

6.9941 6.8618

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Statement of Operations Summary Information:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(257,972</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(190,766</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Weighted-average common shares outstanding - basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,032,466,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,080,043,580</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table>

NOTE 2 – GOING CONCERN During the quarter ended September 30, 2020, the Company was unable to generate cash flows sufficient to support its operations despite Kangzi’s business operation and was dependent on related party advances from the current controlling shareholder. In addition, the Company had experienced recurring net losses, and had an accumulated deficit of $19,156,356 and working capital deficit of $1,116,680 As of September 30, 2020. These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. In light of the impacts of the COVID-19 outbreak, if we are required to operate in a challenging economic environment in China, or incur unanticipated capital expenditures, or decide to accelerate growth, we may need additional financing. As of September 30, 2020, we had borrowed a loan from a shareholder for working capital purposes. The loan is unsecured, non-interest bearing and payable on demand. As of September 30, 2020, we have borrowed from such shareholder a total of $1,116,680 for working capital purposes. We cannot guarantee, however, that additional financing, if required, would be available on favorable terms, if at all. Such financing may include the use of additional debt or the sale of the Company’s equity interests. Any financing which involves the sale of the Company’s equity interests or instruments that are convertible into the Company’s equity interests could result in immediate and possibly significant dilution to our existing shareholders.  There can be no assurance that sufficient funds required during the next year or thereafter will be generated from any future operations or that funds will be available from external sources such as debt or equity financings or other potential sources. If the Company is unable to raise capital from external sources when required, there will be a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing stockholders. Management is now seeking an operating company with which to merge or acquire. In the foreseeable future, the Company will rely on related parties, such as its controlling shareholder, to provide advances to funds general corporate purposes and any potential acquisitions of profitable investments. There is no assurance, however, that the Company will achieve its objectives or goals. 1116680 1116680

NOTE 3 – CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Bank Deposits-China & HK</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,277</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">95,522</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; padding-left: 5.4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,277</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">95,522</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Bank Deposits-China & HK</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,277</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">95,522</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; padding-left: 5.4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,277</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">95,522</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

3277

95522

NOTE 4 – OTHER RECEIVABLE Other receivable consists of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Rental and POS machine deposits</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">14,588</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">14241</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Others</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,058</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61,494</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,499</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">64,646</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">51,236</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> Management periodically reviews account balance. If any indication occurs, the allowance for doubtful debts would be recognized. No such allowance has been recognized during the nine months ended September 30, 2020. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Rental and POS machine deposits</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">14,588</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">14241</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Others</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,058</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61,494</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,499</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">64,646</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">51,236</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

14588

14241

50058

61494

24499

64646

51236

NOTE 5 – ADVANCES TO SUPPLIERS Advances to suppliers consists of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Purchases of scientific research equipment</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">19,055</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">48,344</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19,055</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">48,344</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Purchases of scientific research equipment</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">19,055</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">48,344</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19,055</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">48,344</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

19055

48344

19055

48344

NOTE 6 – INVENTORY Inventory consists of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 0">Working in process</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">434,437</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">421,533</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0">Inventories - raw materials</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">47,001</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">481,438</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">421,533</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> No impairment was provided for the inventories as of September 30, 2020 and December 31, 2019.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 0">Working in process</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">434,437</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">421,533</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0">Inventories - raw materials</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">47,001</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">481,438</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">421,533</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

434437

421533

47001

NOTE 7 – OPERATING LEASE RIGHT-OF-USE ASSET AND LIABILITIES On September 1, 2019, the Company entered in a lease agreement for office space, the right-of-use asset is recognized as following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 0">Operating lease right-of-use asset</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">147,712</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">202,976</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 5.4pt">　</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">147,712</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">202,976</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 11 Operating lease liability consist both current and noncurrent component as the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease liability - current portion</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">75,723</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">31,017</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,655</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">　172,610</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 5.4pt">　</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">150,378</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">203,627</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> ASU 2016-02 requires that public companies use a secured incremental browning rate for the present value of lease payments when the rate implicit in the contract is not readily determinable. We determine a secured rate on a quarterly basis and update the weighted average discount rate accordingly. Lease terms and discount rate follow. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 1, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Weighted Average Remaining Lease Term(Year)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.75</td><td style="text-align: left">%</td></tr> </table> The approximate future minimum lease payments under operating leases as: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0; text-align: justify; text-indent: 0">　</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; width: 88%; text-align: justify; padding-left: 0">Fiscal 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">20,661</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: justify; padding-left: 0">Fiscal 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Fiscal 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,873</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: justify; padding-left: 0.125in">Total Lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161,067</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Less Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,689</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: justify; padding-bottom: 4pt; padding-left: 0.125in">Present value of lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">150,378</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 0">Operating lease right-of-use asset</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">147,712</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">202,976</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 5.4pt">　</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">147,712</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">202,976</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

147712

202976

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease liability - current portion</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">75,723</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">31,017</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,655</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">　172,610</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 5.4pt">　</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">150,378</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">203,627</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

75723

31017

74655

172610

150378

203627

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 1, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Weighted Average Remaining Lease Term(Year)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.75</td><td style="text-align: left">%</td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0; text-align: justify; text-indent: 0">　</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; width: 88%; text-align: justify; padding-left: 0">Fiscal 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">20,661</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: justify; padding-left: 0">Fiscal 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Fiscal 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,873</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: justify; padding-left: 0.125in">Total Lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161,067</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Less Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,689</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: justify; padding-bottom: 4pt; padding-left: 0.125in">Present value of lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">150,378</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

150378

NOTE 8 – ADVANCES FROM CUSTOMERS <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 76%; text-align: left; padding-left: 0">Advances from customers(1)</td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">484,674</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">430,616</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; font-weight: bold; padding-left: 5.4pt">　</td><td style="padding-bottom: 4pt; font-weight: bold"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">484,674</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 4pt; font-weight: bold"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">430,616</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt">(1)</td> <td style="font-size: 10pt; text-align: justify">On October 15, 2019, JSEL entered into a clinical cooperation agreement (the “Clinical Cooperation Agreement”) with Shenzhen Saikun Biotechnology Co., Ltd. (“Saikun”). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of the Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month.</td></tr> </table>

JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of the Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 76%; text-align: left; padding-left: 0">Advances from customers(1)</td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">484,674</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">430,616</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; font-weight: bold; padding-left: 5.4pt">　</td><td style="padding-bottom: 4pt; font-weight: bold"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">484,674</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 4pt; font-weight: bold"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">430,616</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 484674 430616

484674

430616

NOTE 9 – ACCRUED EXPENSES AND OTHER PAYABLES Accrued expenses and other payables consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Accrued payroll</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">88,699</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">30,674</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Other Payables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">147,900</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">80,700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">236,599</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">111,374</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> Accrued payroll includes all company employee payroll liabilities as of September 30, 2020, and other payables contains employee reimbursements. Operating lease liability consist both current and noncurrent component as the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease liability - current portion</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">75,723</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">31,017</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,655</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">172,610</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">150,378</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">203,627</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Accrued payroll</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">88,699</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">30,674</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Other Payables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">147,900</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">80,700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">236,599</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">111,374</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

88699

30674

147900

80700

236599

111374

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease liability - current portion</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">75,723</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">31,017</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,655</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">172,610</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">150,378</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">203,627</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

75723

31017

74655

172610

150378

203627

NOTE 10 – RELATED PARTY TRANSACTIONS As of September 30, 2020 and December 31, 2019, the Company owed related parties $898,344 and $874,749, respectively. As the Company has just started business activities in March 2019, all expenses incurred during this reporting period are paid by a shareholder, who is also a director of the Company. Expenses mainly included auditing, consulting and legal advisory expenses, government registration expenses, and payrolls.

NOTE 11 – EQUITY The Company had not recorded any equity transactions during the nine months ended September 30, 2020. The Company recorded the following equity transactions during the year ended December 31, 2019: On March 15, 2019, the Company, with the approval of the Board, entered into a Share Cancellation Agreement (the “Share Cancellation Agreement”) with Mr. Ban Siong Ang, the President, Chief Executive Officer, and Chairman of the Board of the Company. Pursuant to the Share Cancellation Agreement, the Company and Mr. Ang agreed to cancel 109,006,861 shares of Common Stock previously issued to Mr. Ang.

109006861

NOTE 12 – INCOME TAXES The Company is subject to U.S. Federal tax laws. The Company has not recognized an income tax benefit for its operating losses in the United States because the Company does not expect to commence active operations in the United States. Heyu Healthcare Technology Limited was incorporated in Hong Kong and is subject to Hong Kong profits tax at a tax rate of 16.5%. Since Heyu Healthcare Technology Limited had no taxable income during the reporting period, it has not paid Hong Kong profits taxes. Heyu Healthcare Technology Limited has not recognized an income tax benefit for its operating losses in Hong Kong because the Company does not expect to commence active operations in Hong Kong. The Company has been conducting and plans to continue to conduct its major operations in the PRC through JSEL in accordance with the relevant tax laws and regulations. The corporate income tax rate in China is 25%. The Company has not paid PRC profits taxes, since it had no taxable income during the reporting period.

0.165

0.25

EX-101.SCH 7 hybt-20200930.xsd XBRL SCHEMA FILE 001 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - The Company and Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Cash and Cash Equivalents link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Other Receivable link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Advances to Suppliers link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Inventory link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Advances from Customers link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Accrued Expenses and Other Payables link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Equity link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - The Company and Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Cash and Cash Equivalents (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Other Receivable (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Advances to Suppliers (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Inventory (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Advances from Customers (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Accrued Expenses and Other Payables (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - The Company and Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of lease terms and discount rate link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of future minimum lease payments under operating leases link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of earnings (loss) per share link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Other Receivable (Details) - Schedule of other receivable link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Advances to Suppliers (Details) - Schedule of advances to suppliers link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Inventory (Details) - Schedule of inventory link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of weighted average discount rate link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of maturities of lease liabilities link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Advances from Customers (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Advances from Customers (Details) - Schedule of advances from Customers link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Accrued Expenses and Other Payables (Details) - Schedule of accrued expenses and other payables link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Accrued Expenses and Other Payables (Details) - Schedule of operating lease liability link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Equity (Details) link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 hybt-20200930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 hybt-20200930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 hybt-20200930_lab.xml XBRL LABEL FILE Statement of Financial Position [Abstract] Total current assets Total non-current assets Total Assets Total current liabilities Total noncurrent liabilities Total Liabilities Stockholders’ deficit - HYBT and Subsidiaries Total stockholders’ deficit Balance Balance Total Liabilities and Stockholders’ Deficit Income Statement [Abstract] Gross Profit Total operating expenses Loss on operations before income taxes Net Loss Net Loss Loss for the period Net loss attributable to HYBT shareholders Net loss Total Comprehensive Loss Total comprehensive loss attributable to HYBT shareholders Statement of Cash Flows [Abstract] Net cash used from operating activities Net cash used in financing activities NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT END OF PERIOD Cash and cash equivalents Statement of Stockholders' Equity [Abstract] Balance (in Shares) Balance (in Shares) Consolidated Entities [Axis] Equity Components [Axis] Accounting Policies [Abstract] Schedule of details of the consolidating subsidiaries [Abstract] Ownership [Axis] Schedule of lease terms and discount rate [Abstract] Schedule of future minimum lease payments under operating leases [Abstract] Schedule of foreign currency transactions [Abstract] Schedule of earnings (loss) per share [Abstract] Going Concern [Abstract] Cash and Cash Equivalents [Abstract] Schedule of cash and cash equivalents [Abstract] Geographical [Axis] Other Receivable Disclosure [Abstract] Schedule of other receivable [Abstract] Advances To Suppliers [Abstract] Schedule of advances to suppliers [Abstract] Inventory Disclosure [Abstract] Schedule of inventory [Abstract] Discontinued Operations and Disposal Groups [Abstract] Schedule of right-of-use asset [Abstract] Real Estate, Type of Property [Axis] Schedule of operating lease liability [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Total Schedule of weighted average discount rate [Abstract] Schedule of maturities of lease liabilities [Abstract] Revenue from Contract with Customer [Abstract] Schedule of advances from Customers [Abstract] Payables and Accruals [Abstract] Schedule of accrued expenses and other payables [Abstract] Property Subject to or Available for Operating Lease [Axis] Related Party Transactions [Abstract] Stockholders' Equity Note [Abstract] Income Tax Disclosure [Abstract] Entity Common Stock, Shares Outstanding Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Document Type Entity Central Index Key Entity Current Reporting Status Entity Emerging Growth Company Entity File Number Entity Filer Category Entity Incorporation, State or Country Code Entity Interactive Data Current Entity Registrant Name Entity Shell Company Entity Small Business ASSETS Current Assets Accounts receivables Other receivables, net Prepaid expenses Advances to suppliers Inventory Inventory, net Non-current Assets Operating lease right-of-use asset Toal LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities Accounts payable Accrued expenses and other payable Advances from customers Income tax and other taxes payable Operating lease liability - current portion Related party payables Related party payable Noncurrent liabilities Operating lease liability Stockholders’ Deficit Common stock ($0.001 par value, 2,000,000,000 shares authorized, 1,032,466,000 and 1,032,466,000 shares issued and outstanding respectively as of September 30, 2020 and December 31, 2019, respectively) Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Additional paid-in capital Accumulated other comprehensive income Accumulated deficit Noncontrolling interests in subsidiaries Revenue, net Cost of Revenue Operating expenses Selling expenses Administrative expenses Loss on operations Other Expenses Loss attributable to noncontrolling interests Other Comprehensive (Loss) Income Net loss per share - basic and diluted (in Dollars per share) Net loss per share, basic and diluted Weighted average shares - basic and diluted (in Shares) Weighted-average common shares outstanding - basic and diluted CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Change in assets and liabilities Accounts payable and accrued liabilities Accrued expenses and other payable Income tax and other taxes payable CASH FLOWS FROM INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from related party lending Effect of exchange rate changes on cash SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid for interest Cash paid for income tax Shares cancelled March 20, 2019 Shares cancelled March 20, 2019 (in Shares) Foreign currency translation adjustment Income tax expense Foreign currency translation adjustment Total comprehensive (loss) income attributable to noncontrolling interests Accounts receivable Other receivables, net Prepaid expenses Advances to suppliers Inventory Operating lease right-of-use asset Advances from customers Lease liability Heyu Biological Shareholders’ Equity Common Stock Shares to be cancelled Additional Paid in Capital Other Comprehensive Income (Loss) Accumulated Deficit Non - controlling Interest THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES Schedule of details of the consolidating subsidiaries Name of Company Jurisdiction of Formation Attributable equity interest % Schedule of lease terms and discount rate Weighted Average Remaining Lease Term(Year) Weighted Average Discount Rate Schedule of future minimum lease payments under operating leases Fiscal 2020 Fiscal 2021 Fiscal 2022 Total Lease payments Less Imputed interest Present value of lease liabilities Schedule of foreign currency transactions RMB: US$ exchange rate Nine months ended September 30, RMB: US$ exchange rate Schedule of earnings (loss) per share Statement of Operations Summary Information: GOING CONCERN CASH AND CASH EQUIVALENTS Schedule of cash and cash equivalents OTHER RECEIVABLE Schedule of other receivable Rental and POS machine deposits Others Other receivables, net ADVANCES TO SUPPLIERS Schedule of advances to suppliers Purchases of scientific research equipment Total INVENTORY Schedule of inventory Working in process Inventories - raw materials EX-101.PRE 11 hybt-20200930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2020	Nov. 13, 2020
Document Information Line Items
Entity Registrant Name	Heyu Biological Technology Corp
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		1,032,466,000
Amendment Flag	false
Entity Central Index Key	0001086303
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	000-26731
Entity Incorporation, State or Country Code	NV
Entity Interactive Data Current	Yes

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 3,277	$ 95,522
Accounts receivables		32,842
Other receivables, net	64,646	51,236
Prepaid expenses	27,427
Advances to suppliers	19,055	48,344
Inventory	481,438	421,533
Total current assets	595,843	649,477
Non-current Assets
Operating lease right-of-use asset	147,712	202,976
Total non-current assets	147,712	202,976
Total Assets	743,555	852,453
Current Liabilities
Accounts payable	17,152	80,700
Accrued expenses and other payable	236,599	30,674
Advances from customers	484,674	430,616
Income tax and other taxes payable	31	28
Operating lease liability - current portion	75,723	31,017
Related party payables	898,344	874,749
Total current liabilities	1,712,523	1,447,784
Noncurrent liabilities
Operating lease liability	74,655	172,610
Total noncurrent liabilities	74,655	172,610
Total Liabilities	1,787,178	1,620,394
Stockholders’ Deficit
Common stock ($0.001 par value, 2,000,000,000 shares authorized, 1,032,466,000 and 1,032,466,000 shares issued and outstanding respectively as of September 30, 2020 and December 31, 2019, respectively)	1,032,466	1,032,466
Additional paid-in capital	17,149,050	17,149,050
Accumulated other comprehensive income	(6,493)	12,319
Accumulated deficit	(19,156,356)	(18,909,705)
Stockholders’ deficit - HYBT and Subsidiaries	(981,333)	(715,870)
Noncontrolling interests in subsidiaries	(62,290)	(52,071)
Total stockholders’ deficit	(1,043,623)	(767,941)
Total Liabilities and Stockholders’ Deficit	$ 743,555	$ 852,453

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	1,032,466,000	1,032,466,000
Common stock, shares outstanding	1,032,466,000	1,032,466,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue, net	$ 16,600	$ 7,387	$ 52,383	$ 49,930
Cost of Revenue	5,543	3,666	22,732	28,272
Gross Profit	11,057	3,721	29,651	21,658
Operating expenses
Selling expenses	301	5,992	6,527	1,385
Administrative expenses	88,037	202,505	280,134	209,702
Total operating expenses	88,338	208,497	286,661	211,087
Loss on operations	(77,281)	(204,776)	(257,010)	(189,429)
Other Expenses	(331)	(370)	(962)	(1,337)
Loss on operations before income taxes	(77,612)	(205,146)	(257,972)	(190,766)
Income tax expense
Net Loss	(77,612)	(205,146)	(257,972)	(190,766)
Loss attributable to noncontrolling interests	(2,407)	(20,455)	(11,321)	(18,242)
Net loss attributable to HYBT shareholders	(75,205)	(184,691)	(246,651)	(172,524)
Other Comprehensive (Loss) Income
Foreign currency translation adjustment	(24,912)	12,506	(19,913)	3,418
Total Comprehensive Loss	(100,117)	(172,185)	(266,564)	(169,106)
Total comprehensive (loss) income attributable to noncontrolling interests	2,339	(1,320)	1,101	(226)
Total comprehensive loss attributable to HYBT shareholders	$ (97,778)	$ (173,505)	$ (265,463)	$ (169,332)
Net loss per share - basic and diluted (in Dollars per share)	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Weighted average shares - basic and diluted (in Shares)	1,032,466,000	1,019,289,346	1,032,466,000	1,080,043,580

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (257,972)	$ (190,766)
Change in assets and liabilities
Accounts receivable	32,842
Other receivables, net	(13,410)	(3,242)
Prepaid expenses	(27,427)
Advances to suppliers	29,289	(81,431)
Inventory	(59,905)	(311,134)
Operating lease right-of-use asset	55,264	(209,587)
Accounts payable and accrued liabilities	(63,548)	95,090
Accrued expenses and other payable	205,925
Advances from customers	54,058	420,406
Income tax and other taxes payable	3	(1)
Lease liability	(53,249)	209,798
Net cash used from operating activities	(98,130)	(276,014)
CASH FLOWS FROM INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party lending	23,596	677,945
Net cash used in financing activities	23,596	677,945
Effect of exchange rate changes on cash	(17,711)	12,832
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(92,245)	414,763
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	95,522	37,555
CASH AND CASH EQUIVALENTS AT END OF PERIOD	3,277	452,318
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest
Cash paid for income tax

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Heyu Biological Shareholders’ Equity Common Stock	Heyu Biological Shareholders’ Equity Shares to be cancelled	Heyu Biological Shareholders’ Equity Additional Paid in Capital	Heyu Biological Shareholders’ Equity Other Comprehensive Income (Loss)	Heyu Biological Shareholders’ Equity Accumulated Deficit	Non - controlling Interest	Total
Balance at Dec. 31, 2018	$ 1,141,473	$ (109,007)	$ 17,149,050	$ 2,567	$ (18,421,319)		$ (237,236)
Balance (in Shares) at Dec. 31, 2018	1,141,472,861
Shares cancelled March 20, 2019	$ (109,007)	109,007
Shares cancelled March 20, 2019 (in Shares)	(109,006,861)
Foreign currency translation adjustment				14,378		(1,546)	12,832
Loss for the period					(357,216)	(38,697)	(190,766)
Balance at Sep. 30, 2019	$ 1,032,466		17,149,050	16,945	(18,778,535)	(40,243)	(620,317)
Balance (in Shares) at Sep. 30, 2019	1,032,466,000
Balance at Dec. 31, 2019	$ 1,032,466		17,149,050	12,319	(18,909,705)	(52,071)	(767,941)
Balance (in Shares) at Dec. 31, 2019	1,032,466,000
Foreign currency translation adjustment				(18,812)		1,101	(17,711)
Loss for the period					(246,651)	(11,320)	(257,972)
Balance at Sep. 30, 2020	$ 1,032,466		$ 17,149,050	$ (6,493)	$ (19,156,356)	$ (62,290)	$ (1,043,623)
Balance (in Shares) at Sep. 30, 2020	1,032,466,000

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)

+ Details

XML 18 R7.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES

On July 3, 2018, the Company changed its name to Heyu Biological Technology Corporation and applied for a new ticker symbol “HYBT”.

Basis of Presentation

As of September 30, 2020, the details of the consolidating subsidiaries are as follows:

Name of Company	Jurisdiction of Formation	Attributable equity interest %
HP Technology Limited	British Virgin Islands		100	%

Heyu Healthcare Technology Limited	Hong Kong		100	%

JSEL	PRC		100	%

Kangzi	PRC		60	%

Use of Estimates

Cash Equivalents

Accounts receivable and allowance for doubtful accounts

Inventories

Leases

	September 1, 2019
Weighted Average Remaining Lease Term(Year)		3
Weighted Average Discount Rate		4.75	%

The approximate future minimum lease payments under operating leases as:

	Operating Leases
Fiscal 2020		20,661
Fiscal 2021		83,533
Fiscal 2022		56,873
Total Lease payments		161,067
Less Imputed interest		10,689
Present value of lease liabilities	$	150,378

Foreign Currency

	As of
	September 30, 2020		December 31, 2019
RMB: US$ exchange rate		6.8013		6.9668


	Nine months ended September 30,
	2020		2019
RMB: US$ exchange rate		6.9941		6.8618

General and administrative costs

Income Taxes

The Company’s policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense.

Capital Structure

The Company had 2,000,000,000 shares of common stock authorized, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of September 30, 2020, and December 31, 2019.

Earnings (loss) per share

Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive.

For the nine months ended September 30, 2020 and 2019, there were no potentially dilutive shares.

	For the nine months ended September 30,
	2020			2019
Statement of Operations Summary Information:
Net loss	$	(257,972	)	$	(190,766	)
Weighted-average common shares outstanding - basic and diluted		1,032,466,000			1,080,043,580
Net loss per share, basic and diluted	$	(0.00	)	$	(0.00	)

XML 19 R8.htm IDEA: XBRL DOCUMENT

Going Concern

9 Months Ended

Sep. 30, 2020

Going Concern [Abstract]

GOING CONCERN

NOTE 2 – GOING CONCERN

XML 20 R9.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents

9 Months Ended

Sep. 30, 2020

Cash and Cash Equivalents [Abstract]

CASH AND CASH EQUIVALENTS

NOTE 3 – CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of the following:

	As of September 30, 2020		As of December 31, 2019
Bank Deposits-China & HK		3,277		95,522
	$	3,277	$	95,522

XML 21 R10.htm IDEA: XBRL DOCUMENT

Other Receivable

9 Months Ended

Sep. 30, 2020

Other Receivable Disclosure [Abstract]

OTHER RECEIVABLE

NOTE 4 – OTHER RECEIVABLE

Other receivable consists of the following:

	As of September 30, 2020		As of December 31, 2019
Rental and POS machine deposits		14,588		14241
Others		50,058		61,494
Less: Allowance for doubtful accounts		-		(24,499	)
	$	64,646	$	51,236

XML 22 R11.htm IDEA: XBRL DOCUMENT

Advances to Suppliers

9 Months Ended

Sep. 30, 2020

Advances To Suppliers [Abstract]

ADVANCES TO SUPPLIERS

NOTE 5 – ADVANCES TO SUPPLIERS

Advances to suppliers consists of the following:

	As of September 30, 2020		As of December 31, 2019
Purchases of scientific research equipment		19,055		48,344
	$	19,055	$	48,344

XML 23 R12.htm IDEA: XBRL DOCUMENT

Inventory

9 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

INVENTORY

NOTE 6 – INVENTORY

Inventory consists of the following:

	As of September 30, 2020		As of December 31, 2019
Working in process		434,437		421,533
Inventories - raw materials		47,001		-
	$	481,438	$	421,533

No impairment was provided for the inventories as of September 30, 2020 and December 31, 2019.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities

9 Months Ended

Sep. 30, 2020

Discontinued Operations and Disposal Groups [Abstract]

OPERATING LEASE RIGHT-OF-USE ASSET AND LIABILITIES

NOTE 7 – OPERATING LEASE RIGHT-OF-USE ASSET AND LIABILITIES

On September 1, 2019, the Company entered in a lease agreement for office space, the right-of-use asset is recognized as following:

	As of September 30, 2020		As of December 31, 2019
Operating lease right-of-use asset		147,712		202,976
	$	147,712	$	202,976

Operating lease liability consist both current and noncurrent component as the following:

	As of September 30, 2020			As of December 31, 2019
Operating lease liability - current portion		75,723			31,017
Operating lease liability		74,655			172,610
	$	150,378	)	$	203,627

	September 1, 2019
Weighted Average Remaining Lease Term(Year)		3
Weighted Average Discount Rate		4.75	%

The approximate future minimum lease payments under operating leases as:

	Operating Leases
Fiscal 2020		20,661
Fiscal 2021		83,533
Fiscal 2022		56,873
Total Lease payments		161,067
Less Imputed interest		10,689
Present value of lease liabilities	$	150,378

XML 25 R14.htm IDEA: XBRL DOCUMENT

Advances from Customers

9 Months Ended

Sep. 30, 2020

Revenue from Contract with Customer [Abstract]

ADVANCES FROM CUSTOMERS

NOTE 8 – ADVANCES FROM CUSTOMERS

	As of September 30, 2020		As of December 31, 2019
Advances from customers⁽¹⁾		484,674		430,616
	$	484,674	$	430,616

⁽¹⁾

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Payables

9 Months Ended

Sep. 30, 2020

Payables and Accruals [Abstract]

ACCRUED EXPENSES AND OTHER PAYABLES

NOTE 9 – ACCRUED EXPENSES AND OTHER PAYABLES

Accrued expenses and other payables consist of the following:

	As of September 30, 2020		As of December 31, 2019
Accrued payroll		88,699		30,674
Other Payables		147,900		80,700
	$	236,599	$	111,374

Accrued payroll includes all company employee payroll liabilities as of September 30, 2020, and other payables contains employee reimbursements.

Operating lease liability consist both current and noncurrent component as the following:

	As of September 30, 2020		As of December 31, 2019
Operating lease liability - current portion		75,723		31,017
Operating lease liability		74,655		172,610
	$	150,378	$	203,627

XML 27 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2020

RELATED PARTY TRANSACTIONS

NOTE 10 – RELATED PARTY TRANSACTIONS

XML 28 R17.htm IDEA: XBRL DOCUMENT

Equity

9 Months Ended

Sep. 30, 2020

Stockholders' Equity Note [Abstract]

EQUITY

NOTE 11 – EQUITY

The Company had not recorded any equity transactions during the nine months ended September 30, 2020.

The Company recorded the following equity transactions during the year ended December 31, 2019:

XML 29 R18.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2020

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 12 – INCOME TAXES

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

As of September 30, 2020, the details of the consolidating subsidiaries are as follows:

Name of Company	Jurisdiction of Formation	Attributable equity interest %
HP Technology Limited	British Virgin Islands		100	%

Heyu Healthcare Technology Limited	Hong Kong		100	%

JSEL	PRC		100	%

Kangzi	PRC		60	%

Use of Estimates

Use of Estimates

Cash Equivalents

Cash Equivalents

Accounts receivable and allowance for doubtful accounts

Accounts receivable and allowance for doubtful accounts

Inventories

Inventories

Leases

Leases

	September 1, 2019
Weighted Average Remaining Lease Term(Year)		3
Weighted Average Discount Rate		4.75	%

The approximate future minimum lease payments under operating leases as:

	Operating Leases
Fiscal 2020		20,661
Fiscal 2021		83,533
Fiscal 2022		56,873
Total Lease payments		161,067
Less Imputed interest		10,689
Present value of lease liabilities	$	150,378

Foreign Currency

Foreign Currency

	As of
	September 30, 2020		December 31, 2019
RMB: US$ exchange rate		6.8013		6.9668


	Nine months ended September 30,
	2020		2019
RMB: US$ exchange rate		6.9941		6.8618

General and administrative costs

General and administrative costs

Income Taxes

Income Taxes

The Company’s policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense.

Capital Structure

Capital Structure

The Company had 2,000,000,000 shares of common stock authorized, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of September 30, 2020, and December 31, 2019.

Earnings (loss) per share

Earnings (loss) per share

Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive.

For the nine months ended September 30, 2020 and 2019, there were no potentially dilutive shares.

	For the nine months ended September 30,
	2020			2019
Statement of Operations Summary Information:
Net loss	$	(257,972	)	$	(190,766	)
Weighted-average common shares outstanding - basic and diluted		1,032,466,000			1,080,043,580
Net loss per share, basic and diluted	$	(0.00	)	$	(0.00	)

XML 31 R20.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Schedule of details of the consolidating subsidiaries

Name of Company	Jurisdiction of Formation	Attributable equity interest %
HP Technology Limited	British Virgin Islands		100	%

Heyu Healthcare Technology Limited	Hong Kong		100	%

JSEL	PRC		100	%

Kangzi	PRC		60	%

Schedule of lease terms and discount rate

	September 1, 2019
Weighted Average Remaining Lease Term(Year)		3
Weighted Average Discount Rate		4.75	%

Schedule of future minimum lease payments under operating leases

	Operating Leases
Fiscal 2020		20,661
Fiscal 2021		83,533
Fiscal 2022		56,873
Total Lease payments		161,067
Less Imputed interest		10,689
Present value of lease liabilities	$	150,378

Schedule of foreign currency transactions

	As of
	September 30, 2020		December 31, 2019
RMB: US$ exchange rate		6.8013		6.9668


	Nine months ended September 30,
	2020		2019
RMB: US$ exchange rate		6.9941		6.8618

Schedule of earnings (loss) per share

	For the nine months ended September 30,
	2020			2019
Statement of Operations Summary Information:
Net loss	$	(257,972	)	$	(190,766	)
Weighted-average common shares outstanding - basic and diluted		1,032,466,000			1,080,043,580
Net loss per share, basic and diluted	$	(0.00	)	$	(0.00	)

XML 32 R21.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents (Tables)

9 Months Ended

Sep. 30, 2020

Cash and Cash Equivalents [Abstract]

Schedule of cash and cash equivalents

	As of September 30, 2020		As of December 31, 2019
Bank Deposits-China & HK		3,277		95,522
	$	3,277	$	95,522

XML 33 R22.htm IDEA: XBRL DOCUMENT

Other Receivable (Tables)

9 Months Ended

Sep. 30, 2020

Other Receivable Disclosure [Abstract]

Schedule of other receivable

	As of September 30, 2020		As of December 31, 2019
Rental and POS machine deposits		14,588		14241
Others		50,058		61,494
Less: Allowance for doubtful accounts		-		(24,499	)
	$	64,646	$	51,236

XML 34 R23.htm IDEA: XBRL DOCUMENT

Advances to Suppliers (Tables)

9 Months Ended

Sep. 30, 2020

Advances To Suppliers [Abstract]

Schedule of advances to suppliers

	As of September 30, 2020		As of December 31, 2019
Purchases of scientific research equipment		19,055		48,344
	$	19,055	$	48,344

XML 35 R24.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

9 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Schedule of inventory

	As of September 30, 2020		As of December 31, 2019
Working in process		434,437		421,533
Inventories - raw materials		47,001		-
	$	481,438	$	421,533

XML 36 R25.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities (Tables)

9 Months Ended

Sep. 30, 2020

Discontinued Operations and Disposal Groups [Abstract]

Schedule of right-of-use asset

	As of September 30, 2020		As of December 31, 2019
Operating lease right-of-use asset		147,712		202,976
	$	147,712	$	202,976

Schedule of operating lease liability

	As of September 30, 2020			As of December 31, 2019
Operating lease liability - current portion		75,723			31,017
Operating lease liability		74,655			172,610
	$	150,378	)	$	203,627

Schedule of weighted average discount rate

	September 1, 2019
Weighted Average Remaining Lease Term(Year)		3
Weighted Average Discount Rate		4.75	%

Schedule of maturities of lease liabilities

	Operating Leases
Fiscal 2020		20,661
Fiscal 2021		83,533
Fiscal 2022		56,873
Total Lease payments		161,067
Less Imputed interest		10,689
Present value of lease liabilities	$	150,378

XML 37 R26.htm IDEA: XBRL DOCUMENT

Advances from Customers (Tables)

9 Months Ended

Sep. 30, 2020

Revenue from Contract with Customer [Abstract]

Schedule of advances from customers

	As of September 30, 2020		As of December 31, 2019
Advances from customers⁽¹⁾		484,674		430,616
	$	484,674	$	430,616

XML 38 R27.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Payables (Tables)

9 Months Ended

Sep. 30, 2020

Payables and Accruals [Abstract]

Schedule of accrued expenses and other payables

	As of September 30, 2020		As of December 31, 2019
Accrued payroll		88,699		30,674
Other Payables		147,900		80,700
	$	236,599	$	111,374

Schedule of operating lease liability

	As of September 30, 2020		As of December 31, 2019
Operating lease liability - current portion		75,723		31,017
Operating lease liability		74,655		172,610
	$	150,378	$	203,627

XML 39 R28.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Details) - USD ($)	1 Months Ended
	Apr. 18, 2018	Sep. 30, 2020	Mar. 17, 2020	Dec. 31, 2019	Sep. 01, 2019	Jan. 17, 2019
The Company and Significant Accounting Policies (Details) [Line Items]
Proceeds from sale of assets percentage			2.00%
Revenues of approximately (in Dollars)		$ 21,796
Operating lease right-of-use, assets (in Dollars)					$ 215,298
Office space lease (in Dollars)					$ 215,298
Common stock, shares authorized		2,000,000,000		2,000,000,000
Common stock, par value (in Dollars per share)		$ 0.001		$ 0.001
Number of shares issued and outstanding		1,032,466,000		1,032,466,000
Shanghai Kangzi Medical Technology Co., Ltd., [Member]
The Company and Significant Accounting Policies (Details) [Line Items]
Percentage of issued and outstanding shares of common stock						90.00%
JSEL [Member]
The Company and Significant Accounting Policies (Details) [Line Items]
Percentage of issued and outstanding shares of common stock						60.00%
Share Purchase Agreement [Member]
The Company and Significant Accounting Policies (Details) [Line Items]
Purchaser acquired shares	1,021,051,700
Percentage of issued and outstanding shares of common stock	98.91%
Aggregate purchase price (in Dollars)	$ 335,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries	9 Months Ended
	Sep. 30, 2020
HP Technology Limited [Member]
The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries [Line Items]
Name of Company	HP Technology Limited
Jurisdiction of Formation	British Virgin Islands
Attributable equity interest %	100.00%
Heyu Healthcare Technology Limited [Member]
The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries [Line Items]
Name of Company	Heyu Healthcare Technology Limited
Jurisdiction of Formation	Hong Kong
Attributable equity interest %	100.00%
JSEL [Member]
The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries [Line Items]
Name of Company	JSEL
Jurisdiction of Formation	PRC
Attributable equity interest %	100.00%
Kangzi [Member]
The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries [Line Items]
Name of Company	Kangzi
Jurisdiction of Formation	PRC
Attributable equity interest %	60.00%

XML 41 R30.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Details) - Schedule of lease terms and discount rate	Sep. 01, 2019
Schedule of lease terms and discount rate [Abstract]
Weighted Average Remaining Lease Term(Year)	3 years
Weighted Average Discount Rate	4.75%

XML 42 R31.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Details) - Schedule of future minimum lease payments under operating leases	Sep. 30, 2020 USD ($)
Schedule of future minimum lease payments under operating leases [Abstract]
Fiscal 2020	$ 20,661
Fiscal 2021	83,533
Fiscal 2022	56,873
Total Lease payments	161,067
Less Imputed interest	10,689
Present value of lease liabilities	$ 150,378

XML 43 R32.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions	Sep. 30, 2020	Dec. 31, 2019
Schedule of foreign currency transactions [Abstract]
RMB: US$ exchange rate	6.8013	6.9668
RMB: US$ exchange rate	6.9941	6.8618

XML 44 R33.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Details) - Schedule of earnings (loss) per share - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Schedule of earnings (loss) per share [Abstract]
Net loss	$ (75,205)	$ (184,691)	$ (246,651)	$ (172,524)
Weighted-average common shares outstanding - basic and diluted	1,032,466,000	1,019,289,346	1,032,466,000	1,080,043,580
Net loss per share, basic and diluted	$ 0.00	$ 0.00	$ 0.00	$ 0.00

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 45 R34.htm IDEA: XBRL DOCUMENT

Going Concern (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Going Concern (Textual)
Accumulated deficit	$ (19,156,356)	$ (18,909,705)
Working capital deficit	1,116,680
Borrowed for working capital	$ 1,116,680

XML 46 R35.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 3,277	$ 95,522	$ 452,318	$ 37,555
Bank Deposits-China & HK [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 3,277	$ 95,522

XML 47 R36.htm IDEA: XBRL DOCUMENT

Other Receivable (Details) - Schedule of other receivable - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule of other receivable [Abstract]
Rental and POS machine deposits	$ 14,588	$ 14,241
Others	50,058	61,494
Less: Allowance for doubtful accounts		(24,499)
Other receivables, net	$ 64,646	$ 51,236

XML 48 R37.htm IDEA: XBRL DOCUMENT

Advances to Suppliers (Details) - Schedule of advances to suppliers - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule of advances to suppliers [Abstract]
Purchases of scientific research equipment	$ 19,055	$ 48,344
Total	$ 19,055	$ 48,344

XML 49 R38.htm IDEA: XBRL DOCUMENT

Inventory (Details) - Schedule of inventory - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule of inventory [Abstract]
Working in process	$ 434,437	$ 421,533
Inventories - raw materials	47,001
Inventory, net	$ 481,438	$ 421,533

XML 50 R39.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset [Line Items]
Toal	$ 147,712	$ 202,976
Office space [Member]
Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset [Line Items]
Toal	$ 147,712	$ 202,976

XML 51 R40.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability - Rights of use liability [Member] - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability [Line Items]
Operating lease liability - current portion	$ 75,723	$ 31,017
Operating lease liability	74,655	172,610
Total	$ 150,378	$ 203,627

XML 52 R41.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of weighted average discount rate	Sep. 01, 2019
Schedule of weighted average discount rate [Abstract]
Weighted Average Remaining Lease Term(Year)	3 years
Weighted Average Discount Rate	4.75%

XML 53 R42.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of maturities of lease liabilities	Sep. 30, 2020 USD ($)
Schedule of maturities of lease liabilities [Abstract]
Fiscal 2020	$ 20,661
Fiscal 2021	83,533
Fiscal 2022	56,873
Total Lease payments	161,067
Less Imputed interest	10,689
Present value of lease liabilities	$ 150,378

XML 54 R43.htm IDEA: XBRL DOCUMENT

Advances from Customers (Details)

Oct. 15, 2019

Revenue from Contract with Customer [Abstract]

Advances from customers, description

XML 55 R44.htm IDEA: XBRL DOCUMENT

Advances from Customers (Details) - Schedule of advances from Customers - USD ($)

Sep. 30, 2020

Dec. 31, 2019

Schedule of advances from Customers [Abstract]

Advances from customers

^[1]

$ 484,674

$ 430,616

Total

$ 484,674

$ 430,616

[1]

XML 56 R45.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Payables (Details) - Schedule of accrued expenses and other payables - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule of accrued expenses and other payables [Abstract]
Accrued payroll	$ 88,699	$ 30,674
Other Payables	147,900	80,700
Total accounts payable and accrued expenses	$ 236,599	$ 111,374

XML 57 R46.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Payables (Details) - Schedule of operating lease liability - Operating lease liability [Member] - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Accrued Expenses and Other Payables (Details) - Schedule of operating lease liability [Line Items]
Operating lease liability - current portion	$ 75,723	$ 31,017
Operating lease liability	74,655	172,610
Total	$ 150,378	$ 203,627

XML 58 R47.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Related Party Transactions [Abstract]
Related party payable	$ 898,344	$ 874,749

XML 59 R48.htm IDEA: XBRL DOCUMENT

Equity (Details)	Mar. 15, 2019 shares
Share Cancellation Agreement [Member]
Equity (Details) [Line Items]
Common stock, shares issued	109,006,861

XML 60 R49.htm IDEA: XBRL DOCUMENT

Income Taxes (Details)	9 Months Ended
Income Taxes (Details)	Sep. 30, 2020
Hong Kong [Member]
Income Taxes (Details) [Line Items]
Income tax rate	16.50%
China [Member]
Income Taxes (Details) [Line Items]
Income tax rate	25.00%

EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 66 251 1 true 20 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://heyu.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://heyu.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://heyu.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Unaudited) Sheet http://heyu.com/role/ConsolidatedIncomeStatement Consolidated Statements of Operations and Comprehensive Income (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://heyu.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Sheet http://heyu.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - The Company and Significant Accounting Policies Sheet http://heyu.com/role/TheCompanyandSignificantAccountingPolicies The Company and Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Going Concern Sheet http://heyu.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 008 - Disclosure - Cash and Cash Equivalents Sheet http://heyu.com/role/CashandCashEquivalents Cash and Cash Equivalents Notes 9 false false R10.htm 009 - Disclosure - Other Receivable Sheet http://heyu.com/role/OtherReceivable Other Receivable Notes 10 false false R11.htm 010 - Disclosure - Advances to Suppliers Sheet http://heyu.com/role/AdvancestoSuppliers Advances to Suppliers Notes 11 false false R12.htm 011 - Disclosure - Inventory Sheet http://heyu.com/role/Inventory Inventory Notes 12 false false R13.htm 012 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities Sheet http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilities Operating Lease Right-of-Use Asset and Liabilities Notes 13 false false R14.htm 013 - Disclosure - Advances from Customers Sheet http://heyu.com/role/AdvancesfromCustomers Advances from Customers Notes 14 false false R15.htm 014 - Disclosure - Accrued Expenses and Other Payables Sheet http://heyu.com/role/AccruedExpensesandOtherPayables Accrued Expenses and Other Payables Notes 15 false false R16.htm 015 - Disclosure - Related Party Transactions Sheet http://heyu.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 016 - Disclosure - Equity Sheet http://heyu.com/role/Equity Equity Notes 17 false false R18.htm 017 - Disclosure - Income Taxes Sheet http://heyu.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 018 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://heyu.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://heyu.com/role/TheCompanyandSignificantAccountingPolicies 19 false false R20.htm 019 - Disclosure - The Company and Significant Accounting Policies (Tables) Sheet http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables The Company and Significant Accounting Policies (Tables) Tables http://heyu.com/role/TheCompanyandSignificantAccountingPolicies 20 false false R21.htm 020 - Disclosure - Cash and Cash Equivalents (Tables) Sheet http://heyu.com/role/CashandCashEquivalentsTables Cash and Cash Equivalents (Tables) Tables http://heyu.com/role/CashandCashEquivalents 21 false false R22.htm 021 - Disclosure - Other Receivable (Tables) Sheet http://heyu.com/role/OtherReceivableTables Other Receivable (Tables) Tables http://heyu.com/role/OtherReceivable 22 false false R23.htm 022 - Disclosure - Advances to Suppliers (Tables) Sheet http://heyu.com/role/AdvancestoSuppliersTables Advances to Suppliers (Tables) Tables http://heyu.com/role/AdvancestoSuppliers 23 false false R24.htm 023 - Disclosure - Inventory (Tables) Sheet http://heyu.com/role/InventoryTables Inventory (Tables) Tables http://heyu.com/role/Inventory 24 false false R25.htm 024 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Tables) Sheet http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilitiesTables Operating Lease Right-of-Use Asset and Liabilities (Tables) Tables http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilities 25 false false R26.htm 025 - Disclosure - Advances from Customers (Tables) Sheet http://heyu.com/role/AdvancesfromCustomersTables Advances from Customers (Tables) Tables http://heyu.com/role/AdvancesfromCustomers 26 false false R27.htm 026 - Disclosure - Accrued Expenses and Other Payables (Tables) Sheet http://heyu.com/role/AccruedExpensesandOtherPayablesTables Accrued Expenses and Other Payables (Tables) Tables http://heyu.com/role/AccruedExpensesandOtherPayables 27 false false R28.htm 027 - Disclosure - The Company and Significant Accounting Policies (Details) Sheet http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails The Company and Significant Accounting Policies (Details) Details http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables 28 false false R29.htm 028 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries Sheet http://heyu.com/role/ScheduleofdetailsoftheconsolidatingsubsidiariesTable The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries Details http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables 29 false false R30.htm 029 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of lease terms and discount rate Sheet http://heyu.com/role/ScheduleofleasetermsanddiscountrateTable The Company and Significant Accounting Policies (Details) - Schedule of lease terms and discount rate Details http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables 30 false false R31.htm 030 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of future minimum lease payments under operating leases Sheet http://heyu.com/role/ScheduleoffutureminimumleasepaymentsunderoperatingleasesTable The Company and Significant Accounting Policies (Details) - Schedule of future minimum lease payments under operating leases Details http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables 31 false false R32.htm 031 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions Sheet http://heyu.com/role/ScheduleofforeigncurrencytransactionsTable The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions Details http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables 32 false false R33.htm 032 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of earnings (loss) per share Sheet http://heyu.com/role/ScheduleofearningslosspershareTable The Company and Significant Accounting Policies (Details) - Schedule of earnings (loss) per share Details http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables 33 false false R34.htm 033 - Disclosure - Going Concern (Details) Sheet http://heyu.com/role/GoingConcernDetails Going Concern (Details) Details http://heyu.com/role/GoingConcern 34 false false R35.htm 034 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents Sheet http://heyu.com/role/ScheduleofcashandcashequivalentsTable Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents Details http://heyu.com/role/CashandCashEquivalentsTables 35 false false R36.htm 035 - Disclosure - Other Receivable (Details) - Schedule of other receivable Sheet http://heyu.com/role/ScheduleofotherreceivableTable Other Receivable (Details) - Schedule of other receivable Details http://heyu.com/role/OtherReceivableTables 36 false false R37.htm 036 - Disclosure - Advances to Suppliers (Details) - Schedule of advances to suppliers Sheet http://heyu.com/role/ScheduleofadvancestosuppliersTable Advances to Suppliers (Details) - Schedule of advances to suppliers Details http://heyu.com/role/AdvancestoSuppliersTables 37 false false R38.htm 037 - Disclosure - Inventory (Details) - Schedule of inventory Sheet http://heyu.com/role/ScheduleofinventoryTable Inventory (Details) - Schedule of inventory Details http://heyu.com/role/InventoryTables 38 false false R39.htm 038 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset Sheet http://heyu.com/role/ScheduleofrightofuseassetTable Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset Details http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilitiesTables 39 false false R40.htm 039 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability Sheet http://heyu.com/role/ScheduleofoperatingleaseliabilityTable Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability Details http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilitiesTables 40 false false R41.htm 040 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of weighted average discount rate Sheet http://heyu.com/role/ScheduleofweightedaveragediscountrateTable Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of weighted average discount rate Details http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilitiesTables 41 false false R42.htm 041 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of maturities of lease liabilities Sheet http://heyu.com/role/ScheduleofmaturitiesofleaseliabilitiesTable Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of maturities of lease liabilities Details http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilitiesTables 42 false false R43.htm 042 - Disclosure - Advances from Customers (Details) Sheet http://heyu.com/role/AdvancesfromCustomersDetails Advances from Customers (Details) Details http://heyu.com/role/AdvancesfromCustomersTables 43 false false R44.htm 043 - Disclosure - Advances from Customers (Details) - Schedule of advances from Customers Sheet http://heyu.com/role/ScheduleofadvancesfromCustomersTable Advances from Customers (Details) - Schedule of advances from Customers Details http://heyu.com/role/AdvancesfromCustomersTables 44 false false R45.htm 044 - Disclosure - Accrued Expenses and Other Payables (Details) - Schedule of accrued expenses and other payables Sheet http://heyu.com/role/ScheduleofaccruedexpensesandotherpayablesTable Accrued Expenses and Other Payables (Details) - Schedule of accrued expenses and other payables Details http://heyu.com/role/AccruedExpensesandOtherPayablesTables 45 false false R46.htm 045 - Disclosure - Accrued Expenses and Other Payables (Details) - Schedule of operating lease liability Sheet http://heyu.com/role/ScheduleofoperatingleaseliabilityTable0 Accrued Expenses and Other Payables (Details) - Schedule of operating lease liability Details http://heyu.com/role/AccruedExpensesandOtherPayablesTables 46 false false R47.htm 046 - Disclosure - Related Party Transactions (Details) Sheet http://heyu.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://heyu.com/role/RelatedPartyTransactions 47 false false R48.htm 047 - Disclosure - Equity (Details) Sheet http://heyu.com/role/EquityDetails Equity (Details) Details http://heyu.com/role/Equity 48 false false R49.htm 048 - Disclosure - Income Taxes (Details) Sheet http://heyu.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://heyu.com/role/IncomeTaxes 49 false false All Reports Book All Reports hybt-20200930.xml hybt-20200930.xsd hybt-20200930_cal.xml hybt-20200930_def.xml hybt-20200930_lab.xml hybt-20200930_pre.xml http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/srt/2020-01-31 true true ZIP 66 0001213900-20-037172-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-20-037172-xbrl.zip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
6,ETV11=WUCI ML"PD&'$14GEF384NAS R/2C%0LY+*YLZ';I%.2\X0 3[IR>;371P_$$?/7C3 M&7W@X"#"D+=\!'F]R,?8#Q528&2MTX]@_=T,.@(2NGFG030)"4@J)M546Y)0 M;2@P.=1D5%D*J>@K2<0MC5#;YQ)H7>BZL9NFXA3HUZDU'O%!KPYWO\!-L@X7 MT>31\7P\QT78R*T(9EM#'I:MN'#3I6IRVV]/513"GT0-=A WSMD*& 3(.K$>5 MOJO*W/KE1((OJ+1< MZ/U,*CKB2GR[," 2*U$Y-\Y%*H:;K^_#QS<($%KZZ;?XAV/\0T6()"?INU4X MJSZX'#JL,HQD($A'IM69C[+ZKJ RVI)0J;$3RY4",515%08]V<' Q3E^%[[3 MAQC5X0W02(4G-+7)61DQ^3< ?V3'6&<2/F=X>R$:QC4&E)8[22Z0+G+\'Z$3 MS0+W'%E6/7":"=JDFF AP:H6D'X.TN\!'@!F.)H7#;$G"B(FY5+!7:S.YC\/ M-X== 3'M1G.!?D=Q'"B+!QNVN<;+7#Q80=_9][F,I", &6+QT!"R*A<2_GK5 MG4]MF%CRAI&2$K+A@X.!AJ2($#72$A"[$M)B$ET^ZDO5/&1RD#=Y??Z>3A@Z MW"'"LV1DHX:%2#(RK=$Z6RS)!)4S38EH+U#CKI(#PU'3/8H 6>L05%S9A&W M\3>V65PE>).SQ1J40TPJMP^(8P3\>>#"YT^0$I"I>^-LP#6]O:E8".Z6Z<> M? W0Y[9XS^5,X_)(6:"^*R(U1)=PCUO:!_>X4$POY@ 7O&&;@(>+0#ZR6T8Q M"*2C;%H',HQK2 Q[Y9IV0@IWMH/1/8+W(0J?D@?<7\()^E,G=.A&3PX.(GRY MR8> = S(!MF[F$HPK"XS[$5W.'DN/!]>'W9W,.I-2BH@[9PW)0)\D<#?@?1# M^]JCS8@Z]QN+TCY>,)QHBHS0^S#J3S/4H9KW9=?F%W,] OFW=JT+*C/:?*^O M3,<9E<+"SR<1.G%(VCDI0#?%$?O1RS1T^[A0R,QBUD$E@1%?6FI#CXBM 7&P M2@8 8 C6GSND^%H7*S%)]+Q9.73$%1Q5\ C1?=?)K)T>)8P*WHH-2\=%)%3% M&.S!<'*CUOXIQ&=<4X28*^]DPR[AO8??=(/DVMGUIY8:8&WHH3H*?!DIOP7X M8]MV*ITI=8&@+*^+$ED]0-_O^PI3 VI%850QX(L ^9)R4;$C 31VU/G?6EDG M-;#:.;Y_=HB] ,;]N3_J4,T;JK7Y!>S'GX+\6[N&*I49#>ZW5J8;W96FO@\9 MT-68P9@'@SX_*YABM9JM5[:3X.C,J+6B;"^F2Q=3 BTS)H:7@>9$IC0"%PM! M@$4Z9AR"P6!46SYH2]3/UBC+%\?7,&'>+_H(9*=-9%I*J%CP.]S&E:+55@X/ M*5;5P])9B^RG&CZ&VA 1J?KW9)RQ(X*% ;?*?8751R" B9W;@HCHK#KVQ?*Z M9&_!O>/E.6(#Z@/Z1*;U 14+9K85^;9(&K22[2S%IWJ6%&N%^D*2YTHO@J)F M[ UBS0-NECB(A<&;S^33B Q"HAKWU2+EEI,&9/A8,T!$R]8N#E+ :Q\M_58? MSX\@L_)2G5Y49-RFB4%C [5Z>.6@Z9.0CS"Z"]5(><*C9?,,_RW0]$2O:.=U M&.0W ]ZMGVZH,0>;M=98:#"V#/K\>,.\RIFVUT0,*(PV[BKU#^5ZOG.CG/$0 M.I4_H7%7$!<=EM'?J-[:+FL]IOJ%#)ZRJQC2B#" N22AM85XT=3X.JS4C_S_ M@OHGNMG@U6IL@=M."![2OR<]M\%7(%7<&/O_W9N6(!G0],68R?RVD(R)R1V<5JNQ:)GQN MU9P&[$5J'H99':NV) XD+(S)+!QW3&38,B.HM?WRMG6=HX.RB36/\ MJDU!@E\U)W&>*ZHGPP-),E@8C,EYP^*P1 ^*/DZYAA5&U8#H?GB-EF7,\)9 PGQ F2J*@I*' M>U+R,"\J:].;I2T!'&->DCQV?(Y:N-+\D%1>CNKZ99"9RB[,_,TC@Z';=80/ MP?@[%1L7]F-5?CKY5-^/A?\.>1>));026"+%2-8I& M:0+QU9(<#31[RTJQ0PI*]D+ M5MSA-E:I6OG9\0^49+GN&J3]"MTC<'IT\N[MT3=_^A/Y -_[Z[_)AGAQ MC'V3Q"]0U@@%Z$][2)(A_1?@D-Y;*R1!$&?L@W0;&)%JK /+-7-:"\X%";0D M-L!1*?G@E1> \]#WG2@&Z(Q*Y?BUS3N= L<9%)HAX$%L#6= M^4<]#C92\M92J'9-. E>,D2+NGK-)[\6V#DY/(Q(4S:5C>L Q<5.4I/6=LQ M!@+^<26HLF;M^'*ULO0#"%&C0KU]21+7J*>*4T@O3C\*F6+4II.X\F#I[+W'\(02+-96=+!@J+LS7X_QK@!.2CI$QM4D'V(Y!X'.O MG@##7K&^]&PVA]V!^%Y)/A\N_!#!!QC$Z!J3/J!>AC'.[5MLU\[S0 \S2BA8 M"952P9 =#Y-#R=ZB-U4XP". ;"LV38%HN/:5R:5IFBUAXG@!=&=.%"!-&E>F MSIPT0TBLQ*S&WP[%.$F(I=MPR%EJAB;+TWK>N=3Z.[CIKKP W26RBEDP'D2R M6G.8=M,U$> \*.&.V*'O8[>9EWV-+'YDLQWN8L_UG,BS^^;,XE=5:JC+[5+0 M@C0,'R0/N8!MP]K*)^=WA&]E/-I1'W4>4!JZ=\P7GH8Q.KDR6,-XHH/*E?P)HKTN9_\498-#,>,-^$/9G-F+DF,L*7X7;= M"JM/PBS.49^"J8O5RI->07)>Y@#E7GT;8PRRG38_ZWDW_!.W%W7D"*9^)'P&R"092"S+RF34<9I)CNF>JW-"&RHBT4 MN%M3'+*$Z"%JJ;Q.#WKX5*:QEUM?(L'*J$5_ F$ PG1$&-@MD\1A$O6<::RO MPU457<_".M0!E1%[,@L6"A,9;N6UV3@4CI!M5;'AKU3W]?P:)J483I(D\NX. M"0[078?U._^07A!U)(PK)644>2K+J8S');H"AG?%MGCJRD9-;+4(UR772<(% MG?;U0[^/<-3G.4S_.^BUKCM65NR[3BAS=7 -,GB%H;X&\]:;B"T[L!<):EF) MW(IK2M$@+\&$YOV$"?*RWBS@\< SN M\% 2&>JF@T41>S8D69+E53&5(5'_=IY$AI4$8K1\JC;SCMJ\L_EL,0R/3KH< MH=]#7$T*NA/$%N<^:V"VV)*Y*G$L!A2()B;&S4,]/!GZ)@<&G!1:'@[%4CII M@-%KRZ=F-Z&IBG<'8MI)_M1'F*:Q]P 7LG M?KB)PD?/A>[9RVT,D356.&PF.-F#ETW:UVU8%0L;CA=E+%G/BI/51W!QN?A^ M!2Z6BRNPN)DM)^OY]0B]3#:@9C3P!<%.A795UM?KMRM11],.:L_2J-Z!7SE;]?',B*H4 M)L9/ #T\)8MO$@EVLNJ*8Y9D%2GA2[4T]?I5PMA%.QY1ET=G!/(NC6P?U4-' M(>W*TB)0Y$H$[%7NLSE2@ZA:?M"82F=,;R,45@&_'NI0CD*2A?P7*FL.?;3# M;AE79MS")JZ;Y0:],+39S1O)\LA).EWFUY]G*Y;3Q5;P@2+W)=PM+ +UZR^\ M\ ('73(M^PMY6(S'7\C!4E)T+^;7D^OIZ/V%$D(A(< B':6"/0BP)MCD(@5]FS&@U68J#"D+1V 4[1@ M-@1$: Q(?R:1TM@K;%OBQ RMQ3KPJ: ?#K7"?5$AEEC'Q^ N_/!IEOYBT.-: M:E[3LB:#%"L3Z/;FYG)V-;M>3R[!^7PUO5RL;I>S%5A<@.*L1@;FQ6)Y-5G/ M%]>VY4^%\55)E*:1ODSF,;"XX,=@S6GK4U@X5!LHL.P\_(!%>F!OPZB(B;9\ M*KFE-8D88:"I+2D'M8[/O :2QJ^$M:Z].5"%)/ M:@E=B+2.NXBFCN]#]_P0(3LR#1T>K)ZLY,PV''9RJ+%.KS2H:H-[#>%QX IQ M_P&\/4F+O%H6+S5^UPXK>:)H.^B$@ M^#/$.QN==4[:O("D' ^< H#-QNK#B$Y1BV ,G>V+K,TTC,8P.TP]=-84_4I MY=^F4A[ >TQ<*8.SCHWX,2][FK;^#LUC&]7RI"Q4OQA.1[$=J*AD'VCU]XXG M+XP]X-V;LAU9JJ6B-,GF6JI05;^ >'/F/,/35HI]5Y3LJ.J.6#-VQCI,'+]1 MC/653_*/,\?";R1!ORXA!OH/1H-26K.VY=+7LE0$:(E M"B&-BB_'%W/$X*Q<9&B#!%U\[JPI)D%JI)=3&8YQIB'0HX>V#TFDH,BM^E#* M8]RJ'CHJN>0P7TY 693I<%]KS'030>P1'[#4DW!.&R:S""EF+ ;YB%IL;ARB M1^R'C=4C>/3T8R96OE(-D4F[DT6+FW*5?8DLPSK^U MT M6*=7BZ5,_24FC\XYF.M$'-$X/<0)NOY&4M)%'6A>B&AHB$XU$INZR3ZV>*[Q M:%\^H+ 6V(?54^\!K:55&B#LJY$Z0JRJE,P^WM:U!)TG3+5 6:ZB9,11\O.- M@UM_8U^8$[Q :G>< .5208?1Z8HXUW?&!APH]20K?A.UC&*MD\ M-(2<*)M!<->J^=['Z-0XG'[@3VBA_A$''7&'3CP(UVN9MCMTVBE,),%-B4:= MC<-&TZ4B$3$TH)Q)3VXZ844:,X4:U%FH3UJ*VG9U+%6V*S;D; FGCFPV>S . M)XB,F,TUNQ^1]'"!X02&.Y^-+ 4>0NRFF^ 8 M5 -/YJTL*%M]2X3,;+0NX:]=/P7!NP\\M+&<(,G>77$<>>BCK8:L//BV\I"Q(]I*YUA91]@=<]2% TO#@[:^=73,L MA2'+'> ;N^UVQ91URJ,_8=G-1MLP$/OB<2FC':G4I:J#ULRK!!GI@Y@)7?"Q MD(W=!5^&@/_C$'FQZVU(X@$2](LPVI%X>^NV0P^R4B\0T9%VVFGA>A,OGK(? MADP\Z TW\W?]OE!G>0>J20:0/*05F07@_]K-[^U9H'K8)72J:CW;% 84>2Q> MPV@7DP8B,;D%+-LG@<@ 9\,Q_I0CQDG"HDZ#AQ(\.&LMDPXGY:1&844+.4T(7@M#:O2L6<*=XP7Y'_'4IT.H6&4<;#@E5)$4]<;*1H)B*$B#6/#@ M5S]")WIMT]6J*Q;4/M$J%-//Z^7-5MTM-Q")1C!,DU15'$8GR!0D904Y'PJ6 MUI1L5UF0EEX6F?3]P(66OS@DAPA>H;VQ.^R6I%C;35:8$ET\ZECQW6[]F+^] M(&:^C$T?:$M8&EL"'>Q2\)GAD1<2!8? A5&E>1'YLR4WWB"25K.+>R-YE^;9 M=> U3'(%%L)/59I!J3^'!]@"EB]YNEQFZWEIK)]"; $.DG&DCH1QY:V,HE!,3VV[ZK19KR&L#;H,KTW1A$A"X0A$MD1C MI'JUBJ-0:M_^%I0KC?EZ0ELGS.!JUJ*DCE:E<@O.7-:,6\LA/(I,UI#(KLJS MK)OPO9<\S'=[W-XY=_Y>PV2RPS?(88(-I6:VX7R00XV9Y17'(!M#*:AM10[5 MN%R/490FA5[\#B87;.29JB4'\B&8#5S@XL(NF1&CW0P><:W@\F& T8+2^'. M%(.*AP Q =2/S,8+ ZVTG$/>O;L%>,G#-66VZ2(HXQ*BUBW,H%E-,M+G,^4U M2HUDVH[1QC35+BJ5RH>#/$O)3FW4Q[47P*LP2![B6>!"=X560R*_WYTPVNS0U:$$&+,GJA@A5L0?&@AV M9"2 >"@HQH)W)T?V*C#((9<]0778"D@9D.VI!%3$\A63@I M5=E62),2)30C-LHC.,]NNH$120L^=7K0^#BC%;IC%-KON(*-R==CMG.AE'FSS M\%NETU<5IKEH31WT6&*90\%R6<(!&2!0@?2=S3 X/?Z6EQ -8ND:?Q]")/!3 MO* H4+O^TD<:O>!246#(SH<%3HN;+JZGL^6UM20.+KD+ 6"O2_N>B?NS(4V& M_X-K CTZ/G$#>_$&:?5#-.PY*C^YZ67L>FVU MP[4RKVOE=Y0HTB$1J#AUZ3.:M.ZD,##>\E4)/0E##O<6)N'BY =80AI+P):* M(- -.&E*:=YW&P7#Q>J3?G1*@#'K*A$CQ"K3LOXX6X+E;#I#BN_L'QCR=GAKXL SGVLIA):&:PD;O@7$\(TCQC?)T(*:&_K%Y#O=A M["6#Q"$5L&V\G.>3LYQH),R6'%\WBQ78.9L'[*5ULU&67\F;7*F>3K6%=6OK M5FE5\2$*XWC(,%_>?%;2.C@(\6J(V18-&<:U6J/QUMF;"%W#Q* 568S'KO( M1$6W%6$GW^>7$]G*[!>@-7M MS7YD>K,CMSM7J^[,+JH<$O+1]'V=(5P[-8)DF(G(31Z_#;UE@T M?*5923%^Y2BC6TF#Z+5Z3Z6ASS#Z;%;.,"HJK-A A,(#CO_%HA9O//0EKJ8& M<,B@@YO68P?0?B0=9KD<;9UK;#+HWZNH,">!BTLC#B=@$K,:C[X2X\2+HK=L M;O/L^OU8OFCYX#)&]-U#[0.I,YDN-T1%AE0Y!WZ1MR,$^_=!V>BZ?8U3UU5ZH9CQ? 7'I M/%TYB-*>X^,*3]GU8%BY8PRP=;;\TLQU>J=/&( MH"EGZ+S=A['C?XC"PSZ>!QO_X*)=2$K9X-K1!^B6T52&S+#..!FW_KMBS/*H MWLR6$U*8_'(V6@OJ@;8=+2#5.@G3 (3EV[B3&+3D-!]P(Y[=84DF,G80IR6WM:CO.1I;[ MK"@;*?KHAJ16'M+IR:#= BBD8)H.CU9#3R:BHM%IN-T[U&))<.]-)'%&YQ!0L'>@?QJ)[KNJ33C"'(:E9\ MQB4KLIK/ER5)I52I (3I]% ^.MU+=YC6D'(<*C2BQ/(U;_1+^ C1I8BTDL?M MR9Q-@DO)Y&WE!U5ZTG-;<'C+XB:*8;E8+J[ ]':U7EQ5HU@LU1E2XW6]TI " M/7J*FP()[%1"73#3P2:'8R];0(NAG&@7$7ET^F!082N% MV=5'&KU24%%@MIKF2X>ML#HJX5OQ=.T5ZB=I4K17V7MEN# 4J7F-IV9*("45 MB6(C U.!D;7D2]DUZP"BWT2'LLD/,MH,O8[HHF+!Y-)$ ME:7PIM/E[>PRB6:U:'GH,K\JJ!D7ZM$9( MA'=[3YBQ/UB3FY9*:7KM*B:A_WJ'KE'M/[B:JPF:*G5DI=+79B?,$3ZN$2 MG>S*S#C _7]KI;$->0Y4IK?3!D(:/U:]B]GE9#T[!S>3Y?I'L%Y.KE>3Z7J^ MN+8=&*G!^?I;C1IE4E_J7__K^!C\]/W5YS_^^Z/_C M2W![?GCZ\#[Z]OVGM[_/+HKJ*['[YY]X?W/]Y?:/T[,O[R>W M[__\^(>/]]'TT^73^_/S#\O[IQ\^7_[ZX_UV=_K+S3]7[NEB$B_>7R_OW[C! M^Z=O/IV^__;\]OJ7/]Q^7J_^XWP)H^"'V\V_;E\>@G?)U:_7GZ:+_8?PO#MUIA>G@7_X>?9^ZO_SK[=CM_O'V;"^3JV^^?/]O,%TM MCX\UB_,FB#$/H>^B'3 C+=&OPT2B#E8_3A3IR8W7:I/%C+';<>' M=T\-V7. MUOP;2NO7-]+GP2;0Q MY+2S^@X4<'#C&.!FD(I+GE6=IR$$M8N;(HGTVEQ]O%G#S4,0^N']RZ6W\Q#? MKD@+!ZDK&GNTZ9@2)B8,\?EX \H!(!L!?DK'_-O>54S(C^(*QE^Q3DC(1_AR M^ @=/WG8.%@5=I +*4B&TR"DD&*)"QH+RL$CE1T5_I5R)$T6W7R'?ZQFEPK" M4_G&-7YV;P+?V$ MRCG3C*.1MF!=:RFZ>^[,";[DM4&G#U[@3 +WXR<%AG(!&'>\\K!AL!P/ ?F8 M8S((_-[9[?\"/GX:@;*685 A%L+EJWI:XRC)JUUA?W3R0I4,VF4$C:Q<1-"_ MFI<0%FA37A/&_*RWS.W60[>'>.^@_V])A4&A$' $BP)O95J!YTN<8Q8OMK?5 MG!QY%<$9;C0:F(T'R_U-!N#'F$/U 68;_QP\=#;AME'/WB#1-*RI M!K!$?(HL"=!@F2#9UZ#R.?@)#[ F09*LJSJB>&O6]I!2@*:N_;R'>SR/8URR M),+_Q'6:^X\ MDB ^B6/O/K!T+/ Q,E\2L!O"K%CT^_N(O.Z!?78>@'V$+]"OO "?U'5, HS9.YD8(699BW1@ MFLH;.UFZ#QF,.T=GHZW>SN295JEQ(44/S6#'=: M($P_V?'1D?3P5,LI'N4*A2HK=IT]+(8QO#U4:NB<1*F7?(6=Y 2PG* T!QEU M"C=GE_'_I\(P E.&2_22V;0EZCE]:1=7G Q57G.D6"X!QJRI(4:((1?I0-+= M)KW>T2]_5DT->:85(B-)#TU3(RM-GU5P/8=(/#VY0X4^TJC"H*(@J,&_23\& M;OJUM5."2_B"^>P5ZBF-#%Y&!!4^YT/,*H/ZY"R??1A%X1/:Z3B@]*G.9YNG M 9W83=Y6UZ:YB;,NYRNX2:M3KF!VY7=O Q=&4^SCY M6;#91DF+SJ)1*V_1C5;ZSZE.[,5%_1=T$-R$OK=Y2?]_T"0FR9EM"*X<:LSP M0308V_]9!5JGJ9%M>+:5N%SS8,N30EL&;V.XV,[BA#BI!@D":Q8FXEZ*MH]\$;^H31.9MF"7]C+D7<+$X<^;SOR1S\&&F<[NU.N.66OYPF59 MN[4+>Y&:1SE28M"[#]+4]DVMC ]2@>2??MK$T(!8Z2-C7NBT<66(9 8/Y #M M"F=GL:B*;C=2:0KV"OKHU_%^-R=%WAQ@E_L'^$LJSUH0*HU,3'? M-%,+3X8X9U!2L[(&!VS"V*XMV4TT:K62]$G6X; OO)U&#$3&7!8,1#HF?+[!*HL,F.436PEZ5>O<71U&@EEM?R\ M'#=K#W(2J]>M)FH%-52 &>ZP;@T9FQ! M(@! 5J=^)7GZ>7K>MV#@W8V.X^?H^?'R3?9Q:L=D_F@9L!:"Y;5U.RKKF MD,)=-C=IF]"8@0W$%7V"N)33- QB9(VZ. AR%B1II[IPYWC-(%KM,ER<&0S5 M3>%CP6)Y90#(1X"?TC%V2K;)\2LOTB58L:;_.+T>3\/=/@R0KI<6%?4;+'6B MGN^M-&GA(L"ZJ))O0?%Q6TYL7%1YK*I=3YDK5;^4DO)P3P'2M _>OE]%T@3; M^_G TAV-B5E)?/E7%"5A7$TP6% 4\*.L2-,!L7Z 6'*<&QRIJVPH^1P%WNNYT1YIT@I.] ,)@8T MD+G5L)J4/4"034Y>JBK3@W)^D", 7F4HO ;'H-IE*D,$_XA0 35<0!49\!-! MQVI)7*."7%C?YMBLEUXW-'Z77@#G"=PU0[7M;/$2F_XK"%C;Z<6BQK/;,4J MX&3S2FQ%%Y-'T2M#!LFR+ 1-]:@:$*>D3H,++ZJ'+&OUX'D^R#_5@5:&& MGE_C*HR2>^<>7H9.$"^")73\69PX";QV=C OA[]&0/H]*E6G[3L$C75^*N+% M+).&3M-T',UQ8OA4U61Q?M;JD*2/ OFDQE:(:VR1$EMH5U<::[=,R"C]^A!# M4F1,WL/2^Z0&;UE]XRXLZD;F +W/&*QW7GDU:YN?X047-R##*QB4-A,.SM[#6J%?0;WF]L=\1@/-._75YX M@9? 2^\1NO, X7#OX1Q34A/SRODEC*8^F@Z?JL.]0*JB8/3&J8@<*[N*0#DF M8$ ))]T\\1$@H "!!3 PVT];':6CEGVE04#3QTB8CR4U08L.0&8,-N[DAB(W M!EW$\*=*,7N[A]-OVI"3D#A9Z]6.%GHDU)75R683':";IS<[6:V<&^>%%-#IW[SK=4)3 M@4U](LTNY(2G /D@,XT\:0C:*);0TBAG>X1R(?: MC0M2YK"HPVZ;((:B2 >,^BX=6..,[APF,-NV\=)- O0#)QL&B0'15;,].H W MZ8/51[-_21Z+T=!=,O3%NNU<41;L#R%NPX/7& 7*6I96' "M[%GX/L M>XY>-"Y%(C84,L)=L*9RH\!44U]< "85% \1.9' Y7@.CF^S(Z<,.WCRT(-6 M2'-!E?4!99A)[K>GYR?J:ZS25[PFK&^[AQ6V^V,H>:\XG0$I'E-MQRL M\IN]OSEKU750%X44->Y9K+$FMSD#!XE2E_P=;UP$!(PH9("W8*W-WP:HI@%X MX\VI 0X6BK+ N$O8EP>V7A M?H -Z8:;PRYO/T5C2/?&>B<4IE4^P7[D39ZP M$N?3Q,"%^S#V<(D6+P .B/=PXSD^P-VRHD>8M^@@?3MP3BI\WOB'&%=;OH,! MW'H)@9OW/03[0Q0?\ TT" E*='O% M&S^,#U':NN>>W/@V*9ROQW'GIQ:.%2VZ_P=&(0O0L1/AMZASF/YW'N3=8]?A MZK#?^Q[2H"R63,B.PLK6R5O.HIT3Y\.^MFV,B5=&.X9EZ6%:3S91(P$N>037 M"V_;/#K^ 6*-EK:;C)LOME];O#;Q5R7D#XT(QO58$REJV-TA"[M38E3SD;V= MT&)1WRDM6\A)":(99VS:AJB.F!J[VS234#BT?I=^AB@3Y,^6#/NFOBW*(U?5$6C 7*%EW@<.*8 MJ]A**\$G0O-[!UWN_A*GN@P;#%B7'?#UQ'_!FB[-TR._:.H_B\J.O_8VSR1( M95R=9>VF/V,%M-C6]JP'F5;>C8+>,A]1S%M1BRLR!+# E7 #H1M?H&6M'%Q. M)+023_M:AM1T#894V'-;;8UYE>)I^!KA%A MB*,JJ>CDR1UN+[=A&A?<0=:.)2Y6+2Y)+-PD'U2$&V4ZK?V#.CJUBTJ-M>AJGLI;*4':=]*WFD%?JI-4#9/6_4\6V? M,[KD,YA2\X_5[)*_0\HO+*JF$HD6E9LK,*9>JHT4S^'6VWB)Z%SF#+&G?#A( MM45:M&93JHED%"WA!GJ/> .=%V]?0DTD'FG/YR5$K>U1D:2#25.IU'L-[%2/ M"NYP>]W#Y/#C' <29#')+^*'BXDCKK@'\<\$]@B[]WBUF*5#$V+51HELF M=6L)QEDTD8=H&&J.(1Q_-VT".IU8)_C5@%VJ;ECQI7 M":/J!QEOJQU1MRQPCX4PO.B$UZ M3Q=X(;*OK&V(.AHLGT-M+7;\H/D]&H?N3/,,+%6+00*(Q?-%"4$EX.05!:L MP.\A/@>A.WE$A^,]<;;C($[\SJW 1QDH(WG[E$&5PTMY>IGT :(K.=(*>74Z M)K_JG]G<675,VO2F+I)(0 MM1879.E@\@ 2!_;2#"C^*(L;H?>P9H-7F,EF<]@=<,9M6@P3V]@1?$ [UGN$ M:9;[91C'M$"1S('H_H).0^Q!O.8D%?0ZBTV70[\K:3/M=S@NJI,:>[."=3ACOU42/R\G;.2#6I?"G/F")[G3?&JF+DX-56<\*% M&_2G4O+UJ![4QG=6KT):68A&'3;DI?$&@7M LZL\M#+&6'UGX.!%?V+E+MR< M;)=77B($:QCMXDG@5B^\8K\ <^@HO#I,[#CW?P$QS'EP<#K"@^/ED?2NMW'\ M,E1B&EXF@M 1>0A6@Q0D<:3M)24"F;*AKL/,]D[25$>)O"?J]S93GJ@(M=T' MW)7:ZT H&1#*'60OGIJ'E>#)DQ,5:O!@1Y;;61Y') IO8PZP>7ZP<*(?Y^SE M&K\KU-X?1)>$VL=VF[O0,&+>"RB+-&BZ?KQ1#>!D#; HX4R<6D07+-?">Q9# MXRFG:4RA?#J6S,"8 M]J;!7)JEW#^U^G#"@>,(@)6M!"=)!X.9,Y\$MM4G^_Z_'(>VZ?3)CE_O^H!G M76S3R\D\C@_0G03NXI#$N%$T8BK3$R$<:<\G(42M[9V0I(-)3=.]J#?M]:$; M5'MVT>@JIIM[:#US@B_G:6G\>/K@!0Y"7*3M>&-L:D >7BTFB1=N3E,**Y_2 M-AMWD#7]V'/)5[.A\G)% NEA7Z*1%NM9#E0LT1AO\KZS-Q'<.U[>&CGW^ =N M6>R,4V\4C\R;4MMR,LHOI,H2U>4;.#IRE"B17^CBM-BNG6<6*VI#0-9MYQ6. M%WM]!-!@7#@1#3\"DR2)O+M#@J]CN*3OC8.7:&,;2:R6QB\A<4S='B5R5?DV439"IX%EJNN'_X*YJCTCY!4FL4"!IFK<>(C]4 M8( 2"/@)@P$$CI4^R\JKI8JW&JD,GQ5HIV',T$GVZ+G0/7NYC:$[#PI3 ]G< MWJ-<.5"DDP@S6NJK%4&CN5*67F M53-'KU+X\9 @/7+E!=[NL%MBP]-'>.'W!QQ;7K\U*"8$8BLC!0\R^""= .0S MD#90Y>9.)\E:0@*:_K8A";W0BB8C/3+!H#E:R5#)S6.!Q"[^=9D*#[^Q+>>QB!(.$52T^_!>7'H%8FP"SE6LYAQ1(=+^?PCN-8JK9+ M>56"0 ;&:Y!! 00,P' LZ375Y=+=3RJD,FK[4Q[OIWR'(!D!*D.([ZDP 2RK M,^9RJ%I+L'C3%^\P*#ILI1>*S&')"3LO6W+E_L!LS&O;GEKF:JCW9/[2K6Z) M#U$8Q^J;@@RC;(L1[(KJBF3V19L"9N^U#"_*A1)00<$C M):2ED2V(+PCG6=NI&QAYH3L+W'-.%EO^,4B_!NAS<%Y+73-\!:)BW[P#<99H MTF-_[L7[,'9\M+T/^QBI7?^ 0VI(PARZI04'Z):QJ@J._!PN2 $?@0(TJ,(& M)? CH8O?TB'6E42T'=@/V0WXAK"H3I"21+1]$/)\NW5>[Z!%=9"=H8-08Y+]'55_9U MB$,)T/9% 'UBPR80H<+DIO93?GT:D,]CF?D=J:08 B!/>+-F:AX3QSP7L[]; MO0OD2%!/IMH"S!)/LC*2*$:F @:DES+)K6;;TE! MA:R&S,CTU6>*C*_(\>>!"Y\_069*3O:NE7T-R.< ?6_M4D?%GOZP15VBR3V& ME . LO#$!"_LQ"%BI&E<)?+P>71&V0#91!!U28=Z05.DQP,]:I/6:-&:QF" M0(\T4P_X8,?F\<(Z[,9UR*R='\ A3SW#+P5R56G2KZA71!L[D5F(AK%3%@>RX2 ?#W( $,X A48=G>+Y#II?%(BD<&3Z.P0 M>P&,X\D&61VQAY%(':&Y=RM+A5Y$^+]8A]$2I9DYJ!ET4 %_E/N3\QFRS0;" M".1S'+4NV+:-^W[H1).,/CE@.I8_#417N..54?H2MS@[0?O,-=&8)Z:!69.% MFGTHF6_9#B 92](EC?*30_(01MZO[$.M;C!F_M]RV'B, MQN:"!/8C??U&\SKQXQJZCW_O)0]Y\:RR91]?F>5CP1,:#/+1M0MR.VS4#H/$ MBZ1S2I8XAO7?;+?WPQ<(LQ!C2H:+3/)_#N4XRL*QZ<'Q5EBFMD(:\W1H9/J^ M3/5 3I*I$T4O2&47U\NWM-W' 0>'0:8@TMNU5>^4U"JIVT^>/"95YLR) M C0[+OJ1=@N0LSKR83B8,3W"I(P..[N/OT3J=I.ABN']U4[H)4XSF:<>Q53H M-!A!]CG-\G'8@2R,"UDW*AOTO6@V*";U79DO:05,?*?(!I=&$,C@8F=+_L<* M:&3.)O5N''8>UCH0AOK,UIG09K-":H\AC9"+)=PY7I#_$7<>8?I56X]%K3"6 M ECZ!<#@QI0D*EZ[^#%)EGYF[YVY<^_&\5Q.@=["1XJ_.\*.\2RZ?9IV?,;W MM,*1>D0M/Z%(01B^X+?L\(+FX,<=ZR[Y&BAE]CRVW;$26T6?3UT=?"GW[ MLA=MORB8Y'V(["==K)V!)[2FO5D&A! M7W9, NH::(+.6:SYNB);+\&)"BR_)D[::.1QE!FF-V&$7^O5$Z?LU!3)EDI_ M3*T3PE@&=AK)CBD<[<,T#Y7'Q5[JB+8!/:9FV[XA[92NZ] M#A.H8%]6 ?S>V8?Q7_+0-0QHC*6"I9=,O7>KT?1M5 M\BW&D14H00;:CNM"4+.%=5+/WA+N\>M'<(\]TVQO05Y?)_-F%J- .LS6\R!O M*?2=QUNVT2OG(PP.[+M,_G>KEE:.!/UDJ2[ _(OV&D$6NK;P1];+^F(D6+ZK MJUKJ1+GHVVHYDZ M7:BW[LYT-NHA:2.9)YE(NARI?"_2=L;E891>+/4U6(U2QM\4B46-+[>/\-Q) M'$&.<1%R4@S"'0 'Z Z[#B,2J3FIF&]H$XA:M>M6IK1[OZCKT<&E]$BS?]G'S8 M[WV(KPB.CT.\+_SP:9;^0EC#L3HVC8/'HT$^?#SU_V462;4RI(DSCC;8."(\ MKK=NUFPV5$"BYX6-J,409F H7,.L/:)72D\F7&40.JC3R- M^*PEFB6T9+]ET1$GV[<:MZW&S5+0UED_01]=L:_0?>?![HN&&@VH)Z,&%4W7 M\=INX299;*NU:10C&N1HKN M$IV?D;=!]\PLA;?^BVHR+PF*;?W)&R=:1"31S25V85Z\2ZX. M)QJ-C>UT?&9I%\7-K)=\%"Z2RGQ9VACEV"4R\"%D-&RX9R MC/;.JJ9)2B:#6M9B-92ICWWM-9F]JI1]Y/';R'RWQ\WGD M?'3ZA)2-KY37PE[6%(9=TU9NG?1G)'D*62O$S<_LJ![[MO,ZF,@+CG-;B5/M M[(;"&LR*6<@VO*45RV"F@_12-,.2ZZP7BE%=:SWRPJ@!>.4%851QZG;/#AIC MP93F*FDLI%/"?)\K5O=J78'JU$:\CZUN1X7W24;& = _I^Q4J9H$KGR:8#60 M$;N*TJ]M:W;1:@0>>0X%C)[H1>1DL^9YHP>S>G JK49\J[.UX%IN-395B2+4 M([H+<6U&I(KNE8WPTY%$7M$70;UIYX#5:V1 M.,,;J5%PW7#P*&L95;*+EVM4V,M+;(SC@/BR7OF8V"GC"*NA+H%_86^MU7K_ MBGP7YE'=%5QU:VV4'ZY)8'T%>DY[JE+%RGO#613U6Q(0P:&ZG[E1Q/=C<2SR>4K!-S-G.8LL% M8">^'SXY:#T7870>'NZ2[<%O;DB1+96# -LP CF0MA(;BXTEOV(JUU0)9CH_ M-7O3D2S[7GFNDDF2M/F*)5':G;]ZLU4"FFTE%X'V MRSGR%M*7BH* 8\N_$%VP7S/B@RQ['3?RA(8A'E39?1*/H*1*F4U+^>:GVW ?-+(9 M0#X%J,P!RDF.\).'_?R<;F2B2D)?U#?AC<.E$],"@UE%+/[--?VT:+HU@M*0 M%.2K3.&NSW)I2$E#FQ,:,%+#6[A4N3?]$;2X9W@U)!T[H'3LV#[+& M1\.2, M.']F'JR?0NQ79_I.I5-HCG .#>8;@DC>&6Q[4)5)P#5.U.AHT&'7NN6EZ8YR M\>OIB*,L;]1NV@-]'8R0!O:23:NY1^R8BA=!Z0=!\!^PL+!U73H&9RR5W>2* M8?85'GM)=*TG(H&UF$YI+Q!]5U#]/V/8&@S7CSP%;$5(Q\AN=ZL%FW>'8G1HW4BRN9I5[>*GWI*[\Z @P?>O[M6'MP]DE,P=MO3\PR_V2<$"2GQWE81"?0<1Q6-18A/'L.8F<,$+[PXE>Y@G48M5!5J';]67KW#\EB>QM#\H[.2L=K)5:2<-9%U>F]61I=Z<>>LWR(AKF)1'%VL_ MM-KY"AO5V*J-5JZ%1G7*8@T[M3CO WE. [W\@/ U3?PX4V:;C*8]:G=ZJ+[" MJ%!Y'.4,"\7=N9QA>:R-O9PA9!6X_+I!VE[1R21CG?4>62B-=)]:?J$T2<-C=5="6VX+BBIII2^$4O>R?,R5.F@T46B<%9$ M8Y>0 ./HU%P^7NCFBI401IL@5J(H=URQB&,Z+::(XXMQ? M.KX/W?-#A"N:$ <5J5K)C0X%^7!$(.(?&FWR5R)<97"[!79>R$O*NA*AE-7B@Z/ZTF\0$O\&-Y8 MLVEQ7NW0D7:6]8 12#3Y%N0?6VNV3$&<+MB4M=G)2JR_^_(%NW846WX@;>// ME>?F,DW6W9!H0^6V>;7_7B*]:(EG$T4"&KZYT+(9<6?4,,#5>2K) MC;+>1'KJ: :2\+X*=*2AS=I4HOJ9B2Z("?P/HR8!ES%-L8.@_1CRY9$#7&VB=Q8F]D<7EH>"NV%?VRY-U() M-XS5V;N'? ]QA"IT)X_HM_?PW(O)X8B?Q[*70ND+2@X*9+! #HSQ\CB*ZXMX M_>)[C2P-+16;6CI/5PB5R'-\4A88MQGFA$-5BKN@D: 82FR#?/ 1^!"%EBY& ML@NDOVG)$,7D=ES"Q$&W-COC\8G6:K82"#A)WAW3H_'V?'CTI',M8I5HX!,!MFW@L2O*GB=DKU% M9=".)%[RY/)#K5@L6B2AFC4=B&M2!HJR7EG!#2*C[B0FQ3[5ZZ#E%653,&G" M4LPMA6:U#IIXT53>*A/-FE(N',QJW7YK#?V:EV/KVK>Y* 4_N_D[B%AG*PRFL+P+]VT$?LDP'W-QVEQ< S3]Z MB."V6"I9YM:)[\A:LX%HS6]/WD _B?/?'./?')^<'K\[_?HY=G_'F,%LW[WJ MU)A.-,,G_R@S<*P^ -#940]G:JVIKF'UV'^);J6DAL2@(E#.8CQ0KHF!6!KP MIX!\:[V<+)M-5-&H+[)J($D)!RY\6?9D9 .-K<@%^E=3)MC M#8D$$P&61&2?H.,>?63GSB/D2%ZOE+VP]'S(L$<"\B6C-OH-^L<=.E3PDOX? M4$L#!!0 ( +96<%&7.P/*<2< +U< @ 5 :'EB="TR,#(P,#DS,%]P M&UL[3U9<]LXTN_[*[S9E^^K*8_M'.-D:F:W9%EV/'$LKR5GCJVM%$U" M$A.*T("D;>77+\!#X@&0 @0HLMQZ>W= Q2XT/_Y MQ='WAR_V@&]#Q_7G/[^XG>P/)L.+BQ?_^N?>WM]^^OO^_MXY\ &R0N#LW:WW MAG"YFMCNWA19?C"#:+GW?^'R__?V]Q9AN/KQX.#AX>%[&_\FL%T$ A@A&P3D M+_;V]S' #.00 0+PQ[V/T-^[@O=[1S_L'1W^^/+-CV]>[8TFT[V7AR\/DT_^ M]I/G^E_OK #L8;K]X.<7.4R/=\C['J+YP'W#Z_B M7Q^]>_?N(/[7S4\#E_9##/;HX+>/EQ-[ 9;6ONL'H>7;!$'@_AC$?WD);2N, M.=E(UQ[S%^3_[6<_VR=_M7_T/@?,BX=O>WD\(>N &S/9BRG\,UROP M\XO 7:X\0E#\=PL$9IB0]5VX3SAX^.[5(0'Q#_(WG]'G(?0#Z+D.X?V)Y9&E M3!8 A"_V".C;FXO-(A9@'1&Q'9!_.&!^=_!/S91]OK80\,,%"%W;\@)90LM@ MM-!]@8UH"28A_O,2(Q.AM?PIH4\]@4,K6)QY\$&$LLTW!^K4<++ TEA S\$^ M:/1GY(;K*0;R$J)73935?(GI4T+<= &(C[/\M>4[$W?NNS.L,WXXL&T8^2%V MDM>8-[8+&I51 )(Z>9]##!<+T ;(;R*P\%N%*H=5!J^8_(?(Z-[RL$HWFR[] M*W5DC;'YHQM@ PS[CGQ53T_YYPKU?^#<$\\4A' 2K5:>BY6YB1K:)\J$>KTAL@?7P$N"M[\:=+T(XNPW ( @ WFN=2]>Z0,\LL?@S1D[6+J1BDF==JGZN+*ALV2DU0N M(.J()@D-)_( G#E8@*X7P!G&9V\.?EC40707N(YKH4RHC8W22P1)<1@,)D@ZM M8R">J[,$@P P+2$I" MD&XV""TZ92!,I0$%5& ?0_VNH+T4;_6(N^BD_32P$>4G[505$;Q M6Y0/@/ (.-8]1CT'+?;%1D@Z_,'2PGM7'&&F&[-7BCGYZ6\&I4<"%C,>%7<6 M%!CJ=VHKB4K!-BJ-_>HJ'Y4*D,X#3?TBZDSM4(W%'JISB/QYB=,DR%:7Z,@ M*EM+_GZ!DUK:)WJ/DIR$U7ZKTEVPL+GY1'Q+4!3335?KO93%<(!/A'\=]>8E(*1(+' M$. SG).12>"*WN8G=H8Q>= N /=(C0-$&6S/N@/>SR^B8']N6:O/FVOK\>S, M]3$XU_*N8> 2.@=W 8X+[+#$O82LN 9B9@5W<2%$"NZ &&0_4W,Y_W# MH[0>XA]">!-]%UY3G-@*=%)?PG"P87Y>S -4)-I"=D8+_F-!QM6BDO07!ZNX M]F'?7KC>1CV(&Y.38 C97(+( >CG%X>DI @O8T:.8,YEPEDFF3&-(?:F(/[E M-FJ7%-HPS@:$^F571K11-0,2I.MK5585YA@6&;G&&%1N,P;AT$)HC4.!3Y87 ME5VO$A'R(I MW([:RDU$;*6+/$(/5TA&^\[HWM;(?.I*4Y:_[)+E&<77"*PL-[L+TF@I=$2] ML!0&CU*QO3(AMNR$./8W-[O7$;(7Y"I%2Q!2AV][I-EQ0=9S+97GZ_;1B8Q$ M-Q15G9\2"1;@]R34*/(DE<\;(Q%%@6;M87Z/3*K(EU1&/TC("(:6)VE#5]#/ M2*T[2M.#".;'.Q!)T#C/7JRJT$W2@U'J=L:;NAT=)E./T(CXFC0Q;SH-_-J) M_ 9>CZW;Y^5PF @'141694H+FRLX/'D1Z1/,#D3GS<)H=7PJ[3E24LB5(PY\ M9Q)"^VNA:4AG;I ;=WYY/:U9MPMNF<$LHPGAM.2YNA)-0F0@,^R&A07)XIEI;WL: M@2G,51_HE6<-MAWQMAS2K&.9R01T7!RAW['2T!@]X(M)C\HE50EH)>?];#UK MC4)LP-@K[]K$/779:"4Q#]5SX"!/V;0$AY6EP%4=[NN]W)@?'+9I:;J@[/$J5XL+E$OHQ@?JJ;LLX3)@6AT86BFLK?#%] M#>PX\2V-Y5U;KG/A#ZV5BRU43XT9'96IZ$-0=$Q.F:BHS9TQHV44'RSCTE/2 MG8? OB!>P^2[J1+&) RU/%L:CUJ.L,+D6#&SXH*6Y2OJE*LLG9\0]K/?.", MTFD0N06DR]4A>PZL1HZ0@M+F89ZR_52N*ZX<#^B0)@5+3WPSC3\M$JRMSQ,? M71^BN/42"Q\$6FRO@J,'X4^5+X8SGE7%P<[=BYRXDQW%# Q#Y-Y%83SY!9(# M*_1#3 "&-MUIOR<51T]5X.2)CBH)! M%"YPV/!M:V>:Q%U!9]9Y*I!RE8'*KL"4B/8B"**.Q)JB,GW5K$RH&>O491Z4 M2'0 1=&Q*Z=2+6/+XG(]L"$Y5F\CN-<\HOT@/?&3ADECZA.73O04JB%@/BP6O2"7*) M4HR+IK>ORI(Z\8R&\Q=B59I*JM149F M5]"'19HT>E$VLOZ$(34,,SJ,::M09V1"-B23Q2-,8ZIQT ]. 'FN)3=^>?2( M5XF)=GT+K2_PTH/NKFIUDMN3PXA6B9F]U=V0G-K&"8XU-)U"6:AZE#9@^/]\^S))7.V]8F)K5O@W#K/TS5VX@3 M831.J^IS86,7YZC9OJD"P=K%VR>'6N),*J9W77?>%([;#=70UP"YD%S^(-*E M=PJ2_VK-";:GJB>!E@K^9\D04STG=6LX2UYA'*:O,,:OSGB)+)PO41 2_FAJ M9%!!EN&$BS+CY%4Y;G%);"^L\$^Z4*&\@(PENU+RJYK$OB22E(LFXE5 M:]H.:I9 %;DY9=)DO)Q*J"V 9GHXQ6K7L4H9W@75>)ZM%^F\RSVC+FM'RTIS M3ZS M0>^<^IZ4:BG:K()94^BY$;.9;(U-5OMU_35VT'RZNU5M+P#:#R+B=>?#AA>Q&DJMBS6!I+>BIQ=?"?9)7 MKS"\:P3O76 SMT[^LF9JE*/(E2L3O-)4SYES)4PGPV.BSX MKW(7(&\ #=<$YH:59#F%@,RZQ6&X[7J@D"&=PAVP>2UT&MUQU:B2'OFIJ^V2 MO!XN9-)RQ*838C0W*_!B-_PFF$;3+=T_2VQHRA-Y57)O2X\4=J- M-I1P&D_J*95_F:$2M<9L=R D=(INIL^83N$D6JT\%V\V7!T9?)#Z*$=.'DGT MSJBL,:M2F3UPJFFN;#U"TRDZI?9:X*1$D;D*.9>IHCSP"&<1_4%,/HNMA]C+ M+5B0:1)UYXK\<'.LD#[D0+J,*D\G=1N@U5+RI.R>C_3BH')W%(>? MG">E/0)2D*A/5Z)"62 3]TU$00B7 ''M'=0/>[E%T%D@49+>Q4Y %"?7Q9(J M56?NGX'>=(&.!K?/8G2+"N@V=Q!E&HLOD$A%>R40O;3=)K;(U!HSS%CO';#9 MN]_=F32G^,I7W;LN:JL R'DR,*8!-.Q/0@.H;%4X&U^A!J03V@S7@=11\33J M0&KY;'2J/J;4!L")X\X;L++6\?4D&7JU>:EQ?0KNM*@#-^[=K"'A,)Y2#0DG MIPU7F/ OUZR/,+Q;J-$*$6:;?!UN-)L!&WO!T:.]L/PYN,$Z._8)Z5I*L-G8 M3-[)B^X&=4Q3]_:Q5*,$IH'\CTR1O[<\$!<&X(6X=EH]._"=XE_D?DEOG]LT MH>17FW! 2^]%MROH61S2M7Q;C,I1T&R6K*>TB@%VK BM,<'Z7M_C0MRO0PTG M,^5O&U:Q=F&R4-@Z.\E%[.=#P[)_:M(G#)6_*DCD/_+;YZ;CJH=X=9:7K6Z4 M_(7>9@T>O'V*4_@8V6(^CI(:XZ3)E#P\>54I+5!TV5!$87K/%U#OXDU"B5,[ M4..[O<%PM73PE5'T5G0E3BF>V:J]"2_N*2R\4#7%(%Y"].I%B_?I-MZL^?$L M34UY-8BE/=H&_%37[6D)@_S+FRD8K!D@GE*HE=@MEAV*GL2>;2N+-F?&HD(( M4/@YW]HZ\L,DJ?3H\H@!?YX3 ?Y_9?;7PM^)(*9@'H3+]2R1=YF>7(1"R$D> ML".C%"Q__1&0!FM5PJ&!-B$7'D7,I$-EAZ&T-HON4[BT7%^G":483'DQ$8'5 M,:CDO-IM(8GO))H!_3@:XG-C\KL)%:'1 C^V8^/DEOQ=LMYC(?,-'@^L2=-XH?4IO $#$EQH>_"3\O+]-E5/<+=<(B\)M; /&6U-E*"M>UH&<57^JRA MD1J%S(U\)R)[;GGS\U3=0Y&2KQR&.&;",50Z?$N?J!F8>K99LOBE[G9U,&H17JO7<4_6LBE092W$%W&= \0H6*J)>>5T&KW(WOSNQG.93 M5"YMF=L>6IQERZG 71F>K(BR70GO*^GFHG352$'^;$8O9)#2J"Y>#6<\%;[K M8F:^!2YQ=%-9>A+KWPUP %Z#,T9#BYPN3R-$]"]&HZWJB!/SSD0-S6;,P4:% M_1-ZQ)THJA%YIZAWXPS?3MH9%U4=XX2ZD)M/F;S//50+5!C]RVI1[K;)J^:O MLC/B\_S4MG9-F8\J<;R[!^@.ML_!J(D,]52-JHO0=UPCU FA;:5QL=)427BN M23?H ?K.&S^5/1KJ@[47KTT7("U9P.N8X#W(G;FVY8?I\)18=3W7)KU8+2Y^ M*L"T3F%F8Y/,H-7R98JY?8*__ZK%/O@PFS::9@$7C(>3G4J?IM1N2>>03,S M+AT@7\)6\I\SK(,>3U,_%(\D\F!8*MU,0$$E.U?'.AX2!62L46V1EOY'/ZQ@ M857Z55JX9T8#C$87W8"QQ6M_5,"G;F![,(@0T.JL^9&;C&7YI-W<($5EJN*J M'^VV5)H!+?QV3NG[+4^$7'@S%(DL'A.HF'?G &,D":+)/+SHF^IFT_/" MW"1DP<0.99BRD-[6?2]\\J0 $]/46@"F(F0.%N='(=(7WZ] .!O9O!95QVU' M6 J@T9TJZJ-CHVO1NED!JC7VJ,5G^GC((=!B1V =[WH6K5/G7M^FI>/OR/1: MTV3T$E-2>_+VVEXH?8V]9KG)Q8%\M^\-P XO O$<9'(A@/G\JQLN,L@Z+9<7 MM>R=80-\K8;)C=OP?:.@^(NUQ+SL[5<,F)TN*88OCT()2+X8@8&:0#5OV M%,>"IW18O.Y5F%(2%?AN \6P4A.X2!XY:"M)+&(QF:<4D6.:-PL$?ZHIR.C!/ M/L1F6P+%),O)2J/30')/JN.CG .RI]:S+,KVWP>>!Q]((OT,HE,8W86SR-OD M6I)-3SY9*!8*X MZ^T<^ !9'KE2<9:N[Y*%ANX]R&[^.M 324IZM '(\EKAV]BMDEZ=[/,,7#T2 M,YM?ZIZQ4)3V[\*L&Y'V*RW#P41U3V1+S1E+Y]E= Q2WQW8@XR:4_3F=-3)/ MYD%MYFZ]0VW%TZR@YZ^4N9[8"^!$'AC/3LDP2"\8S[;3R#'\2707N(YKH8Q! M8IT0+<#WPR>VX9^QP=0;FN.3VQ2@95IF&Z^8O"PH*%PVG'2K_NGO^_M[__GU MXZOS=?_/.^79\/_]][=^>1@_GQ^C=\8>77VZGZ\ [OK>_'7J_ MA ?A!/SR[?C5U\';^'CZ)>CDZ_'@]OCM_??O9^CX8?+A^/3T_.;^<-OGRZ__3Z?+8^^ M7/][XAR-!\'X^.IF?N#XQP^O/QP=OSN]O?KRW>VGZ>1/ZRM$_F^W]A^WZX7_ M*OSX[>K#<+PZAU'TRW>+@U='UO#LR/>BKT=?OOUY,Y]^LOSH\MOJYN3U\+NO M7P_^0,?@:S#YX?'#[,Y[=3$.HI=?[./7;Q>3E]:'V3W^\GO\VC\<'I#[]%9V\?1K/HS<7M#^/ /?WP M]NWHS]E_]X:3F_W]G=]0N-1,V86 5#2XH? L"B,$/N*CR#):WA!V>M?I&]'X M6%OLG*CW@VHB1B6$]>C H$@2"N?4R3G4FAQ(J]V3'^[N!YI2W%(W6;R=HRA' MQ^2*VHZ]FA>%P.G2-8B18KC.6=8="/);\>1R0Q,T6IU$GM ,C:T:T%%T:6U< M%/1KFH8H>_M6LUF:M3"5;-C9X#L^C4.(-?UJK-S4@DBJ<*6FI,*U? >$SP'^3L* M62%S@329,% B83[&&4"'H*W41=EE^L,LJB M+36&=J"6-D6<64<*G7.(@BH5H/#S^,'';G'AKO*/FM>$'_B;7.B!_U\Y[*@" M-23!3OT)D3>%G?*;E2<33;R_G@)[X4,/SM>7[M(-@?,1+.\ XK)I]M>&),C4 M3\+MFK6:RD"_QYO_>V!YX<*VR)BH%J+@@F0FVUPO%3X6&"DA_V4RNA200>[G MNZC_^=68>NO[@^7/O[D"/"U\L(/J6UR0RJ3F$]_[.HQ.<\HN>MC. *['L]0A M;0Z6*?5CE/X#&2:;*LF5M>1LKFH!_TFJ2>5,$9_QVTA!V=8NE=F3HSQ^%%A+ M9J\-/4\T*J>JG!H!*LP\=:5ZFXUN\Q#Z[JAAE38S 4$?-9(B5W4Q8+>948_D M=T/2:(K9[Z2U"(C4(DB]J7*C1NP-)R_>P?"0E' M.NQ8F 93EPH2,L[;G#BOC48=M>3FUWP-D(TYUKEJT&AXBJI!Y;7*3$:'7G<6 MMVPODY;MV 6OTH[M",-",..#M^W9%N_"8G2(Q[S-&L1O";I2B[BD@Y9$HL8N M@P+V#/%I!-(*=OU6V4B!B;HT52K -M)FQINXUQ>D]<*?/L#?@86TS"(7)\)( M-L*@KN3Y;WC>.3_%6$7 #NC,EHR_F(,IBD#5^4NCSAC4$[,],"UL2D(O5#\+ MTV*&/BE7O5BNR-B-+%-P!<+!DH2Q>@J1N3";/QVHVF)\KOJZ' M8-2LQ?2<"*V!'?WJQLZ=YI*A3'8ZE"DL#V5J55-8-R-<\J#& 5'>^Y6@CQ[M MA>7/0=S>M!UHKB6#QHO:='C-+]&:8?%LQIJJOZDA,*@1/5U=N8$9+U 4%"<_ ME]2=A+IUAR =0.;!(%B1>Q)2BM3R-B$;:G:)86:#S23=7RVH%G<(>,=+AK@3 MP#K<6Q&!^2".1R9Y!U9BD-&L?BFW?!61DJ/Q+%[#. H#,AD"KZTT.T^'5"4I M,;R'BEM_R/A CNH,M=K.,\H9QBCI4H@FEV42/J.@;&2B?NJG(N-N-SDY& M49+_@-(,P%8AO] \RJ;MSNRH22T%+UR(I1M(Z4 O&?TY&L>!7N:;< P:O*8Q MF>76&5$]))7$<6D8R1N= SA'UFKAVI:GLI6&C<#LK!DAX\NZ8VJXI:!31EQX M8%XFYA22\@]EPF,B,%?[WJBQ&V&QN9.+G(6]W(GE?ST%*QBX83!?] M!X$>@EH I@XEW)RM7[[ZJ4I]< W<&U^Q]%_I]CH(AQ9":QPG?K(\/5=E?(C- MNG7.V*-9:A5^JCQM=QAB0S+?!!7'$;=((Y6F&TN&U"PH+4Z9F4_2H?@;V.93 M1@W\S^OUEB-FRS^+% ?G"!][=1:5U>'KE0#K.6?T%2/:(^EE)M,^[1 -\,+?"]+=M2KU*E%V!L$/#SF$S^@"1N"G4&7F>AWV]SK2E\1* CQ&H&5Y6:SY70; AV;V3P7YP,#/%PS7(%&I0H? M$JY@6J2B9YQ?,U:S98B-:IX7+P\/U8JY0Q?G%EZ2D'=LFX<")-U9]7MI)[8! M]2M$7R_\:P2Q*6LY3S$PF.+)S]DBB3:M%E7[$:)P;LW!);3\8.S? ,L;!>2^[10$-G)7 MA(-3#&,\NXZ;E\.URDMX2>PF3I.Z7$1V*RPKB(XG8=:22D9)9=016M5>^HNB M->(.VMM4HT*PN%PN'A ?69L*C,4M[B_$0 7W<1^UY<]=/_-YLOYH?8%HZ&'_R7FV$N^?%4!OJBY!MT\I=-R* MB*/K"NIXZ4&\,6Z?!^0OXZWYW&0Y@H0%$(G5,4/]U<834W>]NU,E_%80?V]G MM'8UW:V"L8?'+]Y(@AV+5_FNM,9'E5;H+7-H1OJ$G(6,8;NZ-3 M)XSW@G ;"(=86QD[),_6F[N9?$C;SZVD_9P^YUK#2^B2YW >B*IR6<_#KCF/ MF0)BWI%QU\\#KWNN'GI'7G?MA)?)X_4X^DB?'?"V\4B[+.C'#>1T\'@NTI%T MP5P@]IU$]*/S3,H-;J0 SJQ?,4 MZNMO)E36K M$@8-HR"$RWR[:MN&U;,\U)8MJW18HM>>5&A<%-&_W(V6TUH^$_UE+-OLD64( M_9A08H0945US* M34C38G2.C:@=U2L)+_<5NHX=*44_E)\&L=/%Z"4?8I5\B/H"=*4(S2SV4JC( M7#E2XT^["%26JU6O4C6YW R@I.EL$MU] 78XA6,TN,96$ SL/R,W<&/>:#JQLE"9$E([P\L[ M:R83570N*Q,K^2,"_#.AE BXB-2T/39H>Y-,2QPLS7L2RNR2YQJO(V0OR+EX MCH&2ZC:!G$ M@!ZPN9X!1IZPB(=*/?CD665WI7+(7A&HH=-I>V]'X8]\6:XG M>:XH$*%VO%T9K+F7[*A:6!$!W0T)>B%_OK#<#_@_W]R/P"'ONDV!O?"A!^?K M(;P,'3&?Q MN!WDKP@PC_NF7R>A20!JYGQMR.;7LSJ]&775_+QUKF_-3KA!: M]CJ+LEN3Y^["=5;V&UP$002<,2+_)<07WAA/_[6C@%*&LK[LN+6I/E52,MP[ M05E&VGYKS<%X]@D2OFR6E$;<72D7#R5&KMNTJQ*7#-2EDK6XJ;+^QQT)@R# M[#+DGNHI,A,#=>R5&H2B:N<7Z^&!-@!.7$H^L>(BR'@*VM8&N.(K#C ]]A4\ M3#+5A'4#[H$?D=:RP6J%X*.[M$+@E>^4&,/Y&-_V)GJD2HO)D51$KSO>[5ES MA@/:4&?NN:IY$+V.Z9K8DTKM39=><3S#*P&3E66#F"H^(94_,E&GK$@FE?6G M4OC!R#NZ>$5+Z$]":']-XO=!%"X@0(N[;0 M&$W(.PA.'"7AK3:F5;.\F6A[[6*%^)LJP-N.=TG: 9UT5T1A0&9*XI5R.6$. M,#T.1'F8E,KOG:) 5'M-S#G$9 ^A;P/D2U:]Y$$(=8%0/Q377<\8E6^(=E:^NUYJ"AHT;@A0'S@C"Y$)D 'V M.-$RBCM63P%V0JZFX2R-6(WX81XC*:>F>D(Y&5=LA9KY8:61Q/*2UV0HL(P[-/=EKQR\M3?!VI/9P8T ;5;.,*.0\:)Y3B M:1N4@1HZ*VMY48LJ\= *%N2]8& GDZDF8([ G'BU6\QG%!\4'#=X^.2^E;HC#[P+*@R(GAM&6ILEVD"RM+1U[@4V2XGB++#S S,,A\V;IL MM$('K-?(&G!*7].5&OYSB,S-6> @PF@7):\&U Q6X.&SP@?0NS"XY"*QW3X6 M)WX6T,,+#Q)X5Y#Y=H 2U6O *'[2+K"!_XQ-^4SBJJT 1>QHS?C4[";'IP_$ MSFAL+QY-G]LMA$3 UN/.6BF$*_2')*[VO(0]LE7Z=4#,6@-OG7XM&]2V'.^, M0K(\GYI'URKW4?J**%FH=L(/U":BF$SJTVBH"Q__$4RM1]#R2+X!1)XN\6 0 M(:UQ3!TZX<-!E0G\@0SK6PGKJX(2"VGJOC?KR3F4@U@64PYM6DE)F7]\K4IV MA7, Y\A:+4CSA,H>*C8",XQOT.BL6:>&+TIZ0\4D]?Z#0.RR^;&IC8)+KPBC MM\M2_R M'V.3)^_6GX=757T/,H4/@/W]'-X?I#].=#[]/V65SP$TURK%Q?S\ MTA5?3NR6.==N'FJBPM%L!NS0O0<;7.1YLAM@0]]V/3=FQ##.I%[X(Q_[=N"D MO]$1 ;2@QI3+X-C@"].,6_"[3S'H*;2C99(/'/EA7)T_@V@9PQ6,1NM "=6A M< $2S+(XP-W S8&CQ9HTQXP_QV(Z>D?^L$_^D#.*6M!JR&3%HHI(+86JW1NG MB.H0*ZV7IOE2%QYMJUE'=?@S,2,XE*I,@ $R/A"17IU=@9/B=;'GF*;.0[I]0( M2E@D3- FLINBTF'SQUL;KJ0!V072\CZN%DD?Y,?#*W4->Z*2'.!E.&0I M9YZE0FA%>+L5 #!%5&*"LMX\2;,"I,C'N\!GB,/)17>J9;\ *(M(U0=(RD8I#0BWXGMA4/8N,M/!MR3IS/8"&>!.=0Z3. MP(I0^[,WE;BAJNM./A*_!LB%CKKXCPZW+_Z/P16%O7'2@MH&I6?X;U3F1\J0 M>^+UF(Q1U@G73E2)#ND15AYV/U(1-;S)3L&=WUAMW?)D:7E>5@FD;),J0NW/ M)E7B1B:?KL?G;PD:+0&:XY#F',&'<)$VU"H3$QUZ+]))M>S)Y-8^:2%I5 O@ M>:J%50#:DYV*QHY,. ;R$-M(-.DK5QJ4IR#[$O!5>9$)IG5*0DXLY!86X1-< M3'9_,FD:3%W$4^"L^(H=GR8LYI-0TJ*D@N^5 M:V2Q*)->^]P%N\3@IP-"T)T5 /+__@=02P$"% ,4 " "V5G!1&!M]J=* M #N[@4 $0 @ $ :'EB="TR,#(P,#DS,"YX;6Q02P$" M% ,4 " "V5G!1:O)YJ! 5 M " 3_$ !H>6)T+3(P,C P.3,P7VQA8BYX;6Q02P$"% ,4 M" "V5G!1ESL#RG$G "]7 ( %0 @ &K%P$ :'EB="TR,#(P B,#DS,%]P&UL4$L%!@ & 8 B@$ $\_ 0 $! end